0001193125-23-039243 | S-4 | XBRL Viewer

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Summary of Reconciliation of Statutory IncomeTax Rate

The following table reconciles the United States statutory income tax rate to the Company’s effective income tax rate:


	Year ended December 31,
	2021			2020			2019
United States statutory rate		21.0	%		21.0	%		21.0	%
State tax, net of federal benefit		1.0	%		4.2	%		1.0	%
Stock-based compensation		(0.7	%)		(0.5	%)		(1.6	%)
Officer compensation		1.5	%		(1.0	%)		(1.3	%)
Deferred rate change		—	%		—	%		—	%
R&D credit		1.4	%		0.8	%		1.8	%
PPP Loan		1.1	%		—	%		—	%
Other		0.1	%		(0.1	)%		0.3	%
Change in valuation allowance		(25.4	%)		(24.4	%)		(21.2	%)

Effective income tax rate		—	%		—	%		—	%

Schedule of Deferred Tax Assets And Liabilities

Deferred assets and liabilities consist of the following:


	December 31,
In Thousands	2021			2020			2019
Net operating losses	$	38,671		$	33,392		$	24,852
Stock-based compensation		2,724			2,531			3,637
Financing lease obligations		3,820			4,574			4,640
Tax credit carry forwards		3,210			2,577			2,106
Compensation		514			339			97
Derivative liability		—			703			—
Other		143			391			307

Gross deferred tax assets		49,082			44,507			35,639
Less valuation allowance		(45,369	)		(39,898	)		(30,888	)

Net deferred tax assets		3,713			4,609			4,751
Fixed assets		(3,667	)		(4,609	)		(4,746	)
Other		(46	)		—			(5	)

Gross deferred tax liabilities		(3,713	)		(4,609	)		(4,751	)
Net deferred tax asset or liability	$	—		$	—		$	—

Leases, Commitments, and Contingencies (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

Lease, Cost [Abstract]

Summary of Rent Expense from Operating Leases

Rent expense from all operating leases was as follows:


	Year ended December 31,
In Thousands	2021		2020		2019
Rent expense from operating leases	$	46	$	83	$	117

Schedule of Noncancelable Future Lease Commitments

Noncancelable future lease commitments are as follows:


In Thousands	Operating Leases		Capital Leases
2022	$	12	$	1,708
2023		—		1,552
2024		—		1,487
2025		—		1,487
2026		—		1,481
After fiscal 2027		—		18,470

Total noncancelable future lease commitments	$	12	$	26,185

Schedule Of Impact Of Adoption Of The Standard On Consolidated Balance Sheet

The impact of adoption on the Company’s December 31, 2021, consolidated balance sheet was as follows:


	As Reported December 31, 2021			Adoption of Lease Standard			As Adjusted December 31, 2021
Assets


Land, buildings, and equipment	$	21,731		$	(16,543	)	$	5,188
Operating lease right-of-use assets		—			14,090			14,090

	$	21,731		$	(2,453	)	$	19,278

Liabilities and stockholders’ equity
Current portion of financing lease obligations	$	370		$	(4)		$	366
Other current liabilities		191			276			467
Financing lease obligations		17,506			(17,371)			135
Operating lease obligations		—			13,814			13,814
Accumulated deficit		(196,092	)		832			(195,260	)

	$	(178,025	)	$	(2,453	)	$	(180,478	)

Summary of Non Cancellable Operating Leases

The Company is obligated under non-cancellable operating leases, primarily for office space and certain equipment, as follows:


	As of September 30, 2022
	Remaining		Right-of-Use
In Thousands	Term (years)		Asset
Roseville, MN lease		15.6	$	13,734
Total			$	13,734

Summary of Lease Cost

The components of lease expense were as follows:


In Thousands	Three Months Ended September 30, 2022		Nine Months Ended September 30, 2022
Finance lease costs	$	57	$	73
Operating lease costs		381		1,174
Variable lease costs		260		717

Total	$	698	$	1,964

Summary of Other Information Related to Leases

Other information related to leases was as follows:


In Thousands except for lease term and discount rate	As of and for Nine Months Ended September 30, 2022
	Operating			Financing
Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows	$	205		$	—
Financing cash flows	$	—		$	353
Weighted average remaining lease term (years)		15.6			0.6
Weighted average discount rate		7.9	%		8.1	%

Summary of Future Minimum Rental Payments

As of September 30, 2022, future minimum payments under operating and finance leases were as follows:


In Thousands	Operating			Financing			Total
Remainder of 2022	$	345		$	25		$	370
2023		1,446			100			1,546
2024		1,480			—			1,480
2025		1,479			—			1,479
2026		1,479			—			1,479
2027		1,479			—			1,479
Thereafter		16,991			—			16,991

		24,699			125			24,824
Less: imputed interest		(10,814	)		(5	)		(10,819	)

Total	$	13,885		$	120		$	14,005

Leases, Commitments, and Contingencies - Summary of Lease Cost (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Lease, Cost [Abstract]
Finance Lease cost	$ 57	$ 73
Operating lease cost	381	1,174
Variable lease cost	260	717
Total	$ 698	$ 1,964

Restructuring Costs - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring Costs [Abstract]
Stock-based compensation	$ 2,890	$ 865	$ 2,090	$ 4,971	$ 9,175
Soybean Products [Member]
Restructuring Costs [Abstract]
Severance and other charges			400	$ 700
Stock-based compensation			$ 900

Income Taxes

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

7. INCOME TAXES

The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a full valuation allowance for deferred tax assets due to the uncertainty that enough taxable income will be generated in the taxing jurisdiction to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying consolidated financial statements.

As of September 30, 2022, there were no material changes to what the Company disclosed regarding tax uncertainties or penalties as of December 31, 2021.

7. INCOME TAXES

The following table reconciles the United States statutory income tax rate to the Company’s effective income tax rate:


	Year ended December 31,
	2021			2020			2019
United States statutory rate		21.0	%		21.0	%		21.0	%
State tax, net of federal benefit		1.0	%		4.2	%		1.0	%
Stock-based compensation		(0.7	%)		(0.5	%)		(1.6	%)
Officer compensation		1.5	%		(1.0	%)		(1.3	%)
Deferred rate change		—	%		—	%		—	%
R&D credit		1.4	%		0.8	%		1.8	%
PPP Loan		1.1	%		—	%		—	%
Other		0.1	%		(0.1	)%		0.3	%
Change in valuation allowance		(25.4	%)		(24.4	%)		(21.2	%)

Effective income tax rate		—	%		—	%		—	%

Deferred assets and liabilities consist of the following:


	December 31,
In Thousands	2021			2020			2019
Net operating losses	$	38,671		$	33,392		$	24,852
Stock-based compensation		2,724			2,531			3,637
Financing lease obligations		3,820			4,574			4,640
Tax credit carry forwards		3,210			2,577			2,106
Compensation		514			339			97
Derivative liability		—			703			—
Other		143			391			307

Gross deferred tax assets		49,082			44,507			35,639
Less valuation allowance		(45,369	)		(39,898	)		(30,888	)

Net deferred tax assets		3,713			4,609			4,751
Fixed assets		(3,667	)		(4,609	)		(4,746	)
Other		(46	)		—			(5	)

Gross deferred tax liabilities		(3,713	)		(4,609	)		(4,751	)
Net deferred tax asset or liability	$	—		$	—		$	—

The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a full valuation allowance for deferred tax assets described above due to the uncertainty that enough taxable income will be generated in the taxing jurisdiction to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying consolidated financial statements.

The Company has $228.5 million of tax loss carryforwards. Of this amount, $55.2 million are state operating loss carryforwards and $173.3 million are federal operating loss carryforwards. The federal carryforward periods are

as follows: $131.3 million do not expire and $41.9 million expire between 2032 and 2037. The state net operating losses will expire between 2027 and 2041, with some amounts having indefinite carryover. The Company also has federal and state R&D credit carryovers of $2.3 million and $1.1 million, which will expire between 2028 and 2041.

The Company is subject to federal income taxes in the United States as well as various state and local jurisdictions. The Company has reviewed its tax positions and concluded that no liability for uncertain tax positions is required as of December 31, 2021. The Company will classify any future interest and penalties as a component of income tax expense if incurred.

The Company does not expect the amount of uncertain tax positions to change significantly in the next twelve months. The Company’s major taxing jurisdictions are in the United States, at both the federal and state levels. The number of years open for examination varies depending on the tax jurisdiction but are generally from 3 to 5 years.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Leases, Commitments, and Contingencies - Summary of Other Information Related to Leases (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows, Operating	$ 205
Operating cash flows, Financing	0
Financing cash flows, Operating	0
Financing cash flows, Financing	$ 353
Operating Lease, Weighted average remaining lease term (years)	15 years 7 months 6 days
Finance Lease, Weighted average remaining lease term (years)	7 months 6 days
Operating Lease, Weighted average discount rate	7.90%
Finance Lease, Weighted average discount rate	8.10%

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Restricted Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 1,035	$ 1,236	$ 2,890	$ 865	$ 2,090	$ 4,971	$ 9,175
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 334	$ 416	$ 992	$ (105)	$ 224	$ 1,155	$ 2,910

Leases, Commitments, and Contingencies - Schedule of Noncancelable Future Lease Commitments (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
2024	$ 1,479
Noncancelable Operating Leases [Member]
2022		$ 12
2023		0
2024		0
2025		0
2026		0
After fiscal 2027		0
Total noncancelable future lease commitments		12
Noncancelable Capital Leases [Member]
2022		1,708
2023		1,552
2024		1,487
2025		1,487
2026		1,481
After fiscal 2027		18,470
Total noncancelable future lease commitments		$ 26,185

Stockholders' Equity

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

Federal Home Loan Banks [Abstract]

Stockholders' Equity

5. STOCKHOLDERS’ EQUITY

Follow-On Public Offering

On February 23, 2022, the Company completed the Follow-On Offering, in which it issued 3,880,000 shares of its common stock, Pre-Funded Warrants to purchase up to 3,880,000 shares of its common stock, and Common Warrants to purchase up to 7,760,000 shares of its common stock. The aggregate offering price for each share of common stock and accompanying Common Warrant was $1.41. The aggregate offering price for each Pre-Funded Warrant and accompanying Common Warrant was $1.4099. In the aggregate, the Company received net proceeds of $10.0 million, after deducting approximately $0.9 million of underwriting discounts and estimated other offering expenses.

Pre-Funded Warrants

Each Pre-Funded Warrant entitled the holder to purchase one share of the Company’s common stock at an exercise price of $

0.0001

per share. The Pre-Funded Warrants were recorded as a component of stockholders’ equity within additional paid-in capital. The Pre-Funded Warrants were exercised in full on May 4, 2022, and subsequently settled with the counterparty.

Common Stock Warrants

Each Common Warrant entitles the holder to purchase one share of common stock at an exercise price of $1.41 per share. The Common Warrants became exercisable on August 23, 2022 and expire on August 23, 2027. The Common Warrants are recorded as a liability in the Company’s consolidated balance sheet. Per the terms of the Common Warrants, a holder of an outstanding warrant is not entitled to exercise any portion of such warrant if, upon exercise of such portion of the warrant, the holder’s ownership of the Company’s common stock (together with its affiliates) or the combined voting power of the Company’s securities beneficially owned by such holder (together with its affiliates) would exceed the 4.99 percent after giving effect to the exercise.

Warrant transactions for the nine months ended September 30, 2022, are as follows:


	Number of Pre- Funded Warrants		Weighted Average Exercise Price		Number of Common Warrants		Weighted Average Exercise Price
Outstanding as of December 31, 2021:

Issued		3,880,000	$	0.0001		7,760,000	$	1.41
Forfeited/canceled		—		—		—		—
Exercised		3,880,000	$	0.0001		—

Outstanding as of September 30, 2022:		—		—		7,760,000	$	1.41

Exercisable as of September 30, 2022:		—		—		7,760,000	$	1.41

ATM Facility

On September 21, 2021, the Company entered into an ATM Facility with Jefferies LLC, as sole selling agent. On October 3, 2022, the Company entered into an amendment to the Open Market Sale Agreement that enables it, subject to the applicable baby shelf rules, to offer and sell up to 15,661,000

shares of its common stock. At its discretion the Company determines the timing and number of shares to be issued under the ATM Facility. During the nine months ended September 30, 2022, and in the subsequent period through October 3, 2022, the Company did not issue any shares under the ATM Facility. From October 3, 2022, through the date of this report, the Company has issued approximately

2.0

million shares of common stock under the ATM Facility for proceeds of

0.1

million net of commissions and payments for other share issuance costs.

5. STOCKHOLDERS’ EQUITY

Preferred Stock

Preferred

stock of

50.0

million shares, with a $

0.0001

par value, is authorized but unissued.

Follow-on

Public Offerings

On February

2022

, the Company completed a

follow-on

offering of its common stock and warrants. It issued

3,880,000

shares of its common stock,

pre-funded

warrants to purchase up to

3,880,000

shares of its common stock, and common warrants to purchase up to

7,760,000

shares of its common stock, all at a price of $

1.41

per share. In the aggregate, the Company received net proceeds of $

10.0

million, after deducting approximately $

0.9

million of underwriting discounts and estimated other offering expenses.

On October

2020

, the Company completed a

follow-on

offering of its common stock. It sold an aggregate of

3,750,000

shares of common stock at a price of $

4.00

per share. In the aggregate, the Company received net proceeds from the

follow-on

offering of $

14.0

million, after deducting $

1.0

million of placement and agent fees and other offering expenses. As part of the

follow-on

offering, Cellectis purchased

1,250,000

shares of common stock for a value of $

5.0

million, the proceeds of which are included in the net proceeds of $

14.0

million.

ATM Facility

On September

21, 2021, the Company entered into an ATM Facility with Jefferies, who is acting as sole selling agent for the ATM Facility. Under the terms of the ATM Facility, the Company may, from

time-to-time,

issue common stock having an aggregate offering value of up to $50.0 million. At its discretion, the Company determines the timing and number of shares to be issued under the ATM Facility.

As of December 31, 2021, the Company had issued approximately 1.4 million shares of common stock under the ATM Facility. The Company’s balance of cash and cash equivalents includes $3.9 million of net proceeds from

those sales, and another $0.2 million of cash was received in early January 2022 following the settlement of those sales with the broker. As of the date of this filing, the Company has not issued any additional shares under the ATM Facility.

Share Repurchases

The Company repurchased $0.8 million of common stock in 2019.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Leases, Commitments, and Contingencies - Summary of Rent Expense from Operating Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating Leases, Rent Expense, Net [Abstract]
Rent expense from operating leases	$ 46	$ 83	$ 117

Leases, Commitments, and Contingencies - Schedule Of Impact Of Adoption Of The Standard On Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Jan. 01, 2022	Dec. 31, 2021	Dec. 31, 2020
Assets
Land, buildings, and equipment	$ 4,859		$ 21,731	$ 22,860
Operating lease right-of-use assets	13,736		0
Liabilities and stockholders' equity
Current portion of financing lease obligations	120		370	364
Other current liabilities	397		191	45
Financing lease obligations	0		17,506	17,876
Operating lease obligations	13,550		0
Accumulated deficit	$ (209,314)		(196,092)	$ (166,893)
Accounting Standards Update 2016-02 [Member]
Assets
Operating lease right-of-use assets		$ 14,100
Liabilities and stockholders' equity
Operating lease obligations		$ 14,100
Cumulative Effect, Period of Adoption, Adjusted Balance [Member] \| Accounting Standards Update 2016-02 [Member]
Assets
Land, buildings, and equipment			5,188
Operating lease right-of-use assets			14,090
Total assets			19,278
Liabilities and stockholders' equity
Current portion of financing lease obligations			366
Other current liabilities			467
Financing lease obligations			135
Operating lease obligations			13,814
Accumulated deficit			(195,260)
Total liabilities and stockholders' equity			(180,478)
Previously Reported [Member] \| Accounting Standards Update 2016-02 [Member]
Assets
Land, buildings, and equipment			21,731
Operating lease right-of-use assets			0
Total assets			21,731
Liabilities and stockholders' equity
Current portion of financing lease obligations			370
Other current liabilities			191
Financing lease obligations			17,506
Operating lease obligations			0
Accumulated deficit			(196,092)
Total liabilities and stockholders' equity			(178,025)
Revision of Prior Period, Accounting Standards Update, Adjustment [Member] \| Accounting Standards Update 2016-02 [Member]
Assets
Land, buildings, and equipment			(16,543)
Operating lease right-of-use assets			14,090
Total assets			(2,453)
Liabilities and stockholders' equity
Current portion of financing lease obligations			(4)
Other current liabilities			276
Financing lease obligations			(17,371)
Operating lease obligations			13,814
Accumulated deficit			832
Total liabilities and stockholders' equity			$ (2,453)

Supplemental Information - Summary of Statements of Certain Statements of Cash Flows Amounts (Detail) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Condensed Financial Information Disclosure [Abstract]
Cash and cash equivalents	$ 7,031		$ 13,823	$ 17,299	$ 58,610
Restricted cash			499	393	388
Non-current restricted cash	0		99	597	1,040
Cash, cash equivalents, and restricted cash	7,205	$ 14,913	14,421	18,289	60,038	$ 95,288
Short-term investments			0	11,698	0
Total	7,205		14,421	29,987	60,038
Interest paid	67	1,072	1,425	1,455	1,472
Receivable from Jefferies for shares issued under ATM Facility	(260)	0	260
Non-cash additions to land, buildings, and equipment	687	0	$ 691	$ 0	$ 414
Cumulative effect of adoption of lease accounting standard on stockholders' equity	832	0
Establishment of right-to-use assets and associated operating lease liabilities	$ 14,090	$ 0

Leases, Commitments, and Contingencies

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Leases, Commitments, and Contingencies

8. LEASES, COMMITMENTS, AND CONTINGENCIES

Leases

The Company’s leases are summarized as follows:

•

A lease for its headquarters and laboratory facilities in Roseville, MN which encompasses approximately 38,000 square feet. The original lease term was 20 years, and the Company holds four 5-year renewal options. Historically, this lease was considered a failed sale leaseback based on the nature of the transactions and was reported as a financing-type lease.

•

An equipment financing arrangement that is considered a financing-type lease. This arrangement has a term of four years for each draw. The Company was required to deposit cash into a restricted account in an amount equal to the future rent payments required by the lease. As of September 30, 2022, restricted cash totaled $0.2 million. The Company has the option to request the return of excess collateral annually in December, and the amount the Company expects to receive is reflected as a current asset.

•

A small number of short-term and immaterial leases for office equipment.

The Company’s adoption of the Standard required it to remove its existing land, buildings, and equipment associated with its headquarters lease as well as the associated liability. The Company assessed the elements of its lease agreement and upon adoption, recorded an operating lease associated with the sale leaseback of land underlying the headquarter facility, and a second operating lease associated with the building. The cumulative effect of the adoption of the Standard was recorded to stockholders’ equity. The impact of adoption on the Company’s December 31, 2021, consolidated balance sheet was as follows:


	As Reported December 31, 2021			Adoption of Lease Standard			As Adjusted December 31, 2021
Assets


Land, buildings, and equipment	$	21,731		$	(16,543	)	$	5,188
Operating lease right-of-use assets		—			14,090			14,090

	$	21,731		$	(2,453	)	$	19,278

Liabilities and stockholders’ equity
Current portion of financing lease obligations	$	370		$	(4)		$	366
Other current liabilities		191			276			467
Financing lease obligations		17,506			(17,371)			135
Operating lease obligations		—			13,814			13,814
Accumulated deficit		(196,092	)		832			(195,260	)

	$	(178,025	)	$	(2,453	)	$	(180,478	)

The Company records its operating lease liabilities at the present value of the future lease payments over the lease term. If the lease term includes options to extend or terminate the lease, those elements are included in the determination of lease term when it is reasonably certain that the option will be exercised. The rate used to determine the present value of future lease payments is the rate stated in the lease agreement, or if not stated, the Company’s incremental borrowing rate is used, up to an effective rate that enables the lease liability to amortize to zero over the lease term. Rent expense for operating leases is recorded in selling, general, and administrative (SG&A) expense in the consolidated statements of operations and in operating cash flows in the consolidated statements of cash flows. The Company also records operating lease right-of-use assets at an initial amount equal to the operating lease liability. Those right-of-use assets are amortized to lease expense within SG&A over the lease term using the effective interest method to ensure the right-of-use asset amortizes to zero concurrent with the associated liability, and the right-of-use asset amortization expense is also reported in operating cash flows in the consolidated statements of cash flows.

The Company records its financing lease liabilities at the present value of the future lease payments over the lease term. If the lease term includes options to extend or terminate the lease, those elements are included in the

determination of lease term when it is reasonably certain that the option will be exercised. The rate used to determine the present value of future lease payments is the rate stated in the lease agreement, or if not stated, the Company’s incremental borrowing rate is used, up to an effective rate that enables the lease liability to amortize to zero over the lease term. Expense associated with financing leases is recorded in interest, net in the consolidated statements of operations and in operating cash flows in the consolidated statements of cash flows.

The Company is obligated under non-cancellable operating leases, primarily for office space and certain equipment, as follows:


	As of September 30, 2022
	Remaining		Right-of-Use
In Thousands	Term (years)		Asset
Roseville, MN lease		15.6	$	13,734
Total			$	13,734

The Roseville, MN lease includes four options to each extend the lease for 5 years. These options to extend the lease are not recognized as part of the right-of-use assets and operating lease liabilities as it is not reasonably certain that the Company will exercise those options. The Company’s agreement does not include options to terminate the lease.

The components of lease expense were as follows:


In Thousands	Three Months Ended September 30, 2022		Nine Months Ended September 30, 2022
Finance lease costs	$	57	$	73
Operating lease costs		381		1,174
Variable lease costs		260		717

Total	$	698	$	1,964

Operating lease cost for short-term leases was not material for the nine months ended September 30, 2022.

Other information related to leases was as follows:


In Thousands except for lease term and discount rate	As of and for Nine Months Ended September 30, 2022
	Operating			Financing
Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows	$	205		$	—
Financing cash flows	$	—		$	353
Weighted average remaining lease term (years)		15.6			0.6
Weighted average discount rate		7.9	%		8.1	%

As of September 30, 2022, future minimum payments under operating and finance leases were as follows:


In Thousands	Operating			Financing			Total
Remainder of 2022	$	345		$	25		$	370
2023		1,446			100			1,546
2024		1,480			—			1,480
2025		1,479			—			1,479
2026		1,479			—			1,479
2027		1,479			—			1,479
Thereafter		16,991			—			16,991

		24,699			125			24,824
Less: imputed interest		(10,814	)		(5	)		(10,819	)

Total	$	13,885		$	120		$	14,005

Litigation and Claims

The Company is not currently a party to any material pending legal proceeding except as disclosed in Note 10.

8. LEASES, OTHER COMMITMENTS, AND CONTINGENCIES

Litigation and Claims

The Company is not currently a party to any material pending legal proceeding.

Leases

The Company leases comprise of its headquarters facility, office equipment, and other items. The Company’s headquarters lease involved the sale of land and improvements to a third party who then constructed the facility. This lease is considered a financing lease.

Sale-Leaseback of Headquarters and Lab Facility

In September 2017, the Company consummated a sale-leaseback transaction with a third party for its corporate headquarters and lab facility.

The Company’s headquarters facility is comprised of a 44,000 square-foot office and lab building, the first pilot BioFactory production system, greenhouses, and outdoor research plots. The Company was deemed the owner for accounting purposes. The lease has a term of twenty years with four options to extend its term for five years each subject to there being no default under the lease terms beyond any cure period and the Company occupying the property at the time of extension. In 2017, the Company received $7.0 million in connection with the sale of the land and uncompleted facility.

The lease commenced in May 2018. Under the lease, the Company pays an annual base rent of eight percent of the total project cost with scheduled increases in rent of 7.5 percent on the sixth, eleventh, and sixteenth anniversaries of the start of the lease commencement as well as on the first day of each renewal term. Currently, the Company pays an annual base rent of $1.4 million.

The Company is also responsible for all operating costs and expenses associated with the property. If the landlord decides to sell the property, the Company has a right of first refusal to purchase the property on the same terms offered to any third party.

Concurrent with entering the lease, Cellectis guaranteed all of the Company’s obligations under the lease agreement. Cellectis’ guarantee of the Company’s obligations will terminate at the end of the second consecutive calendar year in which its tangible net worth exceeds $300 million, as determined in accordance with generally accepted accounting principles. At a point when Cellectis owns 50 percent or less of the Company’s outstanding common stock, the Company has agreed to indemnify Cellectis for any obligations incurred by Cellectis under its guaranty of the obligations under the lease.

Sale-Leaseback of Equipment

The Company also has an equipment financing arrangement that is considered a financing lease. As of December 31, 2021, this arrangement requires aggregate payments of $0.6 million over the next 21 months. The Company was required to deposit cash and cash equivalent amounts equal to the future rent payments as required under the Company’s equipment lease facility. As of December 31, 2021, this restricted cash totaled $0.6 million, and a portion may be requested to be returned in each of December 2022 and December 2023.

Operating Leases

As a lessee, the Company leases a vehicle and office equipment under various operating leases.

Rent expense from all operating leases was as follows:


	Year ended December 31,
In Thousands	2021		2020		2019
Rent expense from operating leases	$	46	$	83	$	117

Noncancelable future lease commitments are as follows:


In Thousands	Operating Leases		Capital Leases
2022	$	12	$	1,708
2023		—		1,552
2024		—		1,487
2025		—		1,487
2026		—		1,481
After fiscal 2027		—		18,470

Total noncancelable future lease commitments	$	12	$	26,185

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	275,000,000	275,000,000	275,000,000
Common stock, shares issued	46,909,420	38,874,146	37,165,196
Common stock, shares outstanding	46,809,268	38,773,994	37,065,044
Treasury stock, shares	100,152	100,152	100,152

Going Concern	9 Months Ended	12 Months Ended
Going Concern	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2. GOING CONCERN The Company has incurred losses since its inception. The Company’s net loss was $14.1 million for the nine months ended September 30, 2022, and it used $15.6 million of cash for operating activities for the nine months ended September 30, 2022. The Company’s primary sources of liquidity are its cash and cash equivalents, with additional liquidity accessible, subject to market conditions and other factors, including limitations that may apply to the Company under applicable SEC and Nasdaq Capital Market (Nasdaq) regulations, from the capital markets, including under the Open Market Sale Agreement SM with Jefferies LLC (as amended, the ATM Facility). As of September 30, 2022, the Company had $7.2 million of cash, cash equivalents, and restricted cash. The Company’s restricted cash is associated with its equipment financing leases and was $0.2 million as of September 30, 2022, with $0.1 million scheduled to be returned in December 2022. Current liabilities were $4.2 million as of September 30, 2022. On October 3, 2022, the Company entered into an amendment to the Open Market Sale Agreement with Jefferies for the ATM Facility that enables it, subject to the applicable baby shelf rules described below, to offer and sell up to 15,661,000 shares of its common stock. At its discretion, the Company determines the timing and number of shares to be issued under the ATM Facility. During the nine months ended September 30, 2022, and in the subsequent period through October 3, 2022, the Company did not issue any shares under the ATM Facility. From October 3, 2022, through the date of this report, the Company has issued approximately 2.0 million shares of common stock under the ATM Facility for proceeds of $0.1 million net of commissions and payments for other share issuance costs. On February 23, 2022, the Company issued 3,880,000 shares of its common stock, Pre-Funded Warrants to purchase up to 3,880,000 shares of its common stock, and Common Warrants to purchase up to 7,760,000 shares of its common stock in the Follow-On Offering. In the aggregate, the Company received net proceeds of $10.0 million, after deducting approximately $0.9 million of underwriting discounts and estimated other offering expenses. The Company has incurred losses since its inception and anticipates that it will continue to generate losses for the next several years. Over the longer term and until the Company can generate cash flows sufficient to support its operating capital requirements, it expects to finance a portion of future cash needs through (i) cash on hand, (ii) commercialization activities, which may result in various types of revenue streams from (a) future product development agreements and technology licenses, including upfront and milestone payments, annual license fees, and royalties; and (b) product sales from its proprietary BioFactory production system; (iii) government or other third-party funding, (iv) public or private equity or debt financings, (v) the execution of an alternative strategic transaction pursuant to the board of directors’ ongoing evaluation process, or (v) a combination of the foregoing. However, capital generated by commercialization activities, if any, is expected to be received over a period of time and near-term additional capital may not be available on reasonable terms, if at all. Although the Company has access to the ATM Facility, based on the Company’s public float, as of the date of the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, the Company is only permitted to utilize a “shelf” registration statement for primary offerings, including the registration statement under which the Company’s ATM Facility is operated, subject to Instruction I.B.6 to Form S-3, which is referred to as the “baby shelf” rules. For so long as the Company’s public float is less than $75,000,000 , it may not sell more than the equivalent of one-third of its public float during any twelve consecutive months pursuant to the baby shelf rules. While alternative public and private transaction structures may be available, these may require additional time and cost, may result in substantial dilution to existing stockholders, particularly in light of the Company’s current stock price, may impose operational restrictions on the Company, and may not be available on attractive terms or at all. Accordingly, the Company continuously assesses market conditions and available financing alternatives. In addition, on September 22, 2022, the Company announced that the board of directors is evaluating a full range of strategic alternatives to maximize shareholder value, including financing alternatives, merger, reverse merger, other business combinations, sale of assets, licensing, or other transactions. The Company’s ability to continue as a going concern will depend on its ability to obtain additional public or private equity or debt financing, obtain government or private grants and other similar types of funding, or to consummate an alternative strategic transaction, attain further operating efficiencies, reduce or contain expenditures, and, ultimately, to generate revenue. The Company believes that its cash, cash equivalents, and restricted cash as of September 30, 2022, considering the $0.1 million of net proceeds realized from the ATM Facility as well as potential additional proceeds from the ATM Facility (up to the maximum amount permitted under the baby shelf rules), the legal settlement discussed in Note 10 to the consolidated financial statements, and taking into account additional efforts in reassessing its discretionary spending, including the implementation of increasingly stringent cost reduction and other cash focused measures to manage liquidity, is sufficient to fund its operations into the second quarter of 2023. The Company’s management has concluded there is substantial doubt regarding its ability to continue as a going concern because it will need to raise additional capital to support its business plan for a period of 12 months or more from the date of this filing. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Management has implemented various cost reduction and other cash-focused measures to manage liquidity. If the Company is unable to raise additional capital in a sufficient amount or on acceptable terms or to consummate an alternative strategic transaction, the Company may have to implement increasingly stringent cost saving measures and significantly delay, scale back, or cease operations, in part or in full. If the Company raises additional funds through the issuance of additional debt or equity securities, including as part of a strategic alternative, it could result in substantial dilution to its existing stockholders and increased fixed payment obligations, and these securities may have rights senior to those of the Company’s shares of common stock. Any of these events could significantly harm the Company’s business, financial condition, and prospects.	2. GOING CONCERN The Company has incurred losses since its inception and its net loss was $29.2 million for the year ended December 31, 2021, and it used $18.8 million of cash for operating activities for the year ended December 31, 2021. The Company’s primary sources of liquidity are its cash and cash equivalents, with additional liquidity accessible, subject to market conditions and other factors, including limitations that may apply to the Company under applicable SEC regulations, from the capital markets, including under its ATM Facility. As of December 31, 2021, the Company had $14.4 million of cash, cash equivalents, and restricted cash. The Company’s restricted cash is associated with its equipment financing leases and was $0.6 million as of December 31, 2021, with $0.5 million scheduled to be returned in December 2022. Current liabilities were $4.9 million as of December 31, 2021. On February 23, 2022 (the February 2022 Offering), the Company issued 3,880,000 shares of its common stock, pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and common warrants to purchase up to 7,760,000 shares of its common stock. In the aggregate, the Company received net proceeds of $10.0 million, after deducting approximately $0.9 million of underwriting discounts and estimated other offering expenses. The Company has incurred losses since its inception and anticipates that it will continue to generate losses for the next several years. Over the longer term and until the Company can generate cash flows sufficient to support its operating capital requirements, it expects to finance a portion of future cash needs through (i) cash on hand, (ii) commercialization activities, which may result in various types of revenue streams from (a) future product development agreements and technology licenses, including upfront and milestone payments, annual license fees, and royalties; and (b) product sales from its proprietary BioFactory production system; (iii) government or other third-party funding, which the Company expects to be more readily available if Cellectis were to own less than 50 percent of the Company’s common stock, (iv) public or private equity or debt financings, or (v) a combination of the foregoing. However, additional capital may not be available on reasonable terms, if at all. For example, based on the Company’s public float, as of the date of the filing of its Annual Report on Form 10-K for the year ended December 31, 2021, the Company is only permitted to utilize a “shelf” registration statement, including the registration statement under which the Company’s the ATM Facility, is operated, subject to Instruction I.B.6 to Form S-3, which is referred to as the “baby shelf” rules. For so long as the Company’s public float is less than $75,000,000, it may not sell more than the equivalent of one-third of its public float during any 12 consecutive months pursuant to the baby shelf rules. Although alternative public and private transaction structures are expected to be available, these may require additional time and cost, may impose operational restrictions on the Company, and may not be available on attractive terms. The Company’s ability to continue as a going concern will depend on its ability to obtain additional public or private equity or debt financing, obtain government or private grants and other similar types of funding, attain further operating efficiencies, reduce or contain expenditures, and, ultimately, to generate revenue. The Company’s cash, cash equivalents, and restricted cash as of December 31, 2021, considering its plan to continue to invest in the growth and scaling of its BioFactory production system and AIML capabilities and the $10.0 million of net proceeds from the February 2022 Offering, is sufficient to fund its operations into late 2022. The Company’s management has concluded there is substantial doubt regarding its ability to continue as a going concern because it anticipates that it will need to raise additional capital to support this business plan for a period of 12 months or more from the date of this filing. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. If the Company is unable to raise additional capital in a sufficient amount or on acceptable terms, management may be required to implement various cost reduction and other cash-focused measures to manage liquidity and the Company may have to significantly delay, scale back, or cease operations, in part or in full. If the Company raises additional funds through the issuance of additional debt or equity securities, it could result in dilution to its existing stockholders and increased fixed payment obligations, and these securities may have rights senior to those of the Company’s shares of common stock. Any of these events could significantly harm the Company’s business, financial condition, and prospects.

Restructuring Costs	12 Months Ended
Restructuring Costs	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Restructuring Costs	13. RESTRUCTURING COSTS On August 4, 2020, the Company approved a move to a streamlined go-to-market strategy for its soybean product line. The impact of the action included staffing adjustments related to soybean processing and product sales, as well as the gradual exit of all supply chain contractual commitments that were not associated with the soybean go-to-market strategy. In the twelve months ended December 31, 2020, the Company recorded $0.7 million of restructuring costs for severance and other related payments, and also recorded a $0.9 million recapture benefit of non-cash stock compensation expense from the forfeiture or modification of unvested stock awards. The Company did not incur any other material costs from the disposal of any assets or contractual terminations in the years ended December 31, 2021, and 2020. As of December 31, 2020, all severance and transitional expenses were recorded, with $0.4 million to be paid during 2021. As of December 31, 2021, all amounts related to the restructuring had been paid.

Supplemental Information - Summary of Components of Interest, Net (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Condensed Financial Information Disclosure [Abstract]
Interest expense	$ (57)	$ (356)	$ (73)	$ (1,075)	$ (1,431)	$ (1,435)	$ (1,490)
Interest income	31	0	44	16	17	557	1,600
Total	$ (47)	$ (356)	$ (80)	$ (1,059)	$ (1,414)	$ (878)	$ 110

Employee Benefit Plan (Tables)

12 Months Ended

Dec. 31, 2021

Postemployment Benefits [Abstract]

Summary of Defined Contribution Plan


	Year ended December 31,
In Thousands	2021		2020		2019
Employee benefit plan expenses	$	274	$	309	$	228

Related-Party Transactions	9 Months Ended	12 Months Ended
Related-Party Transactions	Sep. 30, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
Related-Party Transactions	4. RELATED-PARTY TRANSACTIONS The Company is party to several agreements that govern its relationship with Cellectis, some of which require the Company to make payments to Cellectis. Pursuant to the Company’s management services agreement with Cellectis, it incurred no management fee expenses for the three and nine months ended September 30, 2022, and it incurred nominal management fee expenses for the three and nine months ended September 30, 2021. Cellectis has also guaranteed the lease agreement for the Company’s headquarters. Cellectis’ guarantee of the Company’s obligations under the lease will terminate at the end of the second consecutive calendar year in which the Company’s tangible net worth exceeds $300 million. The Company agreed to indemnify Cellectis for any obligations incurred by Cellectis under its guaranty of the obligations under the lease, effective upon Cellectis’ ownership falling to 50 percent or less of the Company’s outstanding common stock. This indemnification obligation was triggered in October 2022. TALEN ® is the Company’s primary gene editing technology. TALEN ® technology was invented by researchers at the University of Minnesota and Iowa State University and exclusively licensed to Cellectis. The Company obtained an exclusive license for the TALEN ® technology for commercial use in plants from Cellectis. The Company also licenses other technology from Cellectis. Cellectis is entitled to royalties on any revenue the Company generates from sales of products less certain amounts as defined in the license agreement, royalties on certain cumulative revenue thresholds, and a percentage of any sublicense revenues. The Company has incurred nominal license and royalty fees for the three and nine months ended September 30, 2022 and 2021.	4. RELATED-PARTY TRANSACTIONS During the year ended December 31, 2020, Cellectis purchased 1,250,000 shares of common stock in the Company’s follow-on offering at the public offering price of $4.00 per share The Company is party to several agreements that govern its relationship with Cellectis, some of which require the Company to make payments to Cellectis. The Company incurred nominal management fees in 2021 and 2020 as services previously provided by Cellectis were internalized in 2019. For the year ended December 31, 2019, management fees were $1.3 million. Cellectis has also guaranteed the lease agreement for the Company’s headquarters. Cellectis’ guarantee of the Company’s obligations under the lease will terminate at the end of the second consecutive calendar year in which the Company’s tangible net worth exceeds $300 million. At a point when Cellectis owns 50 percent or less of the Company’s outstanding common stock, the Company has agreed to indemnify Cellectis for any obligations incurred by Cellectis under its guaranty of the obligations under the lease. TALEN ® is the Company’s primary gene editing technology. TALEN ® technology was invented by researchers at the University of Minnesota and Iowa State University and exclusively licensed to Cellectis. The Company obtained an exclusive license for the TALEN ® technology for commercial use in plants from Cellectis. The Company also licenses other technology from Cellectis. Cellectis is entitled to royalties on any revenue the Company generates from sales of products less certain amounts as defined in the license agreement, royalties on certain cumulative revenue thresholds, and a percentage of any sublicense revenues. The Company has incurred nominal license and royalty fees for the years ended December 31, 2021, 2020, and 2019.

Stock-Based Compensation - Summary of Fair Values of Performance Stock Units Granted and Assumptions used in Monte Carlo Simulation Pricing Model (Detail) - Performance Stock Units [Member]	12 Months Ended
	Dec. 31, 2021 $ / shares
2021 Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.40%
Expected volatility	90.00%
Expected term (in years)	3 years
2019 Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair values of performance stock units granted	$ 7.06
Risk-free interest rate	1.71%
Expected volatility	75.00%
Expected term (in years)	3 years
At Least Twelve Per Share [Member] \| 2021 Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair values of performance stock units granted	$ 2.16
At Least Fifteen Per Share Member \| 2021 Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair values of performance stock units granted	1.89
At Least Twenty Per Share Member \| 2021 Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair values of performance stock units granted	$ 1.55

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

Text Block [Abstract]

Summary of Fair Value Measurements and Financial Statement Presentation

The fair values of the Company’s financial instruments measured at fair value and their respective levels in the fair value hierarchy as of September 30, 2022, were as follows:


	September 30, 2022								September 30, 2022
	Fair Values of Assets								Fair Values of Liabilities
In Thousands	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Other items reported at fair value:
Common stock warrants	$	—	$	—	$	—	$	—	$	—	$	—	$	402	$	402

Total	$	—	$	—	$	—	$	—	$	—	$	—	$	402	$	402

The fair values of the Company’s financial instruments measured at fair value and their respective levels in the fair value hierarchy as of December 31, 2020, were as follows:


	December 31, 2020								December 31, 2020
	Fair Values of Assets								Fair Values of Liabilities
In Thousands	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Other items reported at fair value:
Short-term investments	$	11,698	$	—	$	—	$	11,698	$	—	$	—	$	—	$	—
Commodity derivative contracts		467		—		—		467		—		—		—		—

Total	$	12,165	$	—	$	—	$	12,165	$	—	$	—	$	—	$	—

Summary of Fair Value of the Common Warrants


	As of September 30, 2022

Estimated fair value of Common Warrants	$	0.05
Assumptions:
Risk-free interest rate		4.1	%
Expected volatility		85.0	%
Expected term to liquidation (in years)		4.9

Subsequent Event	9 Months Ended
Subsequent Event	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Event	10. SUBSEQUENT EVENT In early November 2022, the Company reached a settlement with one of its technology vendors regarding alleged intellectual property infringement. As a result of the settlement, the Company will receive $0.75 million upon execution of an amended master services agreement (MSA) and another $0.75 million by January 31, 2023. The execution of the MSA is anticipated to occur in late 2022.

Share Based Compensation- Summary Of Share Based Compensation Performance Shares Award Outstanding Activity (Detail) - Performance Stock Units [Member]	9 Months Ended
	Sep. 30, 2022 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding as of December 31, 2021:	745,000
Issued	530,000
Forfeited/canceled	(145,000)
Exercised	0
Outstanding as of September 30, 2022:	1,130,000

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk - Summary of Fair Value Measurements and Financial Statement Presentation (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2020
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets		$ 12,165
Fair Values of Liabilities	$ 402
Short Term Investments [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets		11,698
Common Stock Warrants [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Liabilities	402
Level 1 [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets		12,165
Level 1 [Member] \| Short Term Investments [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets		11,698
Level 3 [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Liabilities	402
Level 3 [Member] \| Common Stock Warrants [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Liabilities	$ 402
Commodity Derivative Contracts [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets		467
Commodity Derivative Contracts [Member] \| Level 1 [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets		$ 467

Stock-Based Compensation

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

6. STOCK-BASED COMPENSATION

The Company uses broad-based stock plans to attract and retain highly qualified officers and employees and to help ensure that management’s interests are aligned with those of its shareholders. The Company has also granted equity-based awards to directors, nonemployees, and certain employees of Cellectis.

In December 2014, the Company adopted the Calyxt, Inc. Equity Incentive Plan (2014 Plan), which allowed for the grant of stock options, and in June 2017, it adopted the 2017 Omnibus Plan (2017 Plan), which allowed for the grant of stock options, restricted stock units, performance stock units and other types of equity awards. In July 2021, the Company also adopted the Calyxt, Inc. Employee Inducement Incentive Plan (the Inducement Plan), from which PSUs were granted to Michael A. Carr.

On February 19, 2021, James Blome ceased serving as the Company’s Chief Executive Officer. In the nine-month period ended September 30, 2021, the Company recorded a benefit to earnings from a $2.5 million recapture of non-cash stock compensation expense from the forfeiture of Mr. Blome’s unvested stock options, RSUs, and PSUs.

As of September 30, 2022,

2,712,803

shares were registered and available for grant under effective registration statements, while

3,105,208

shares were available for grant in the form of stock options, restricted stock, restricted stock units, and performance stock units under the 2017 Plan. Stock-based awards currently outstanding also include awards granted under the 2014 Plan and the Inducement Plan. No further awards will be granted under either the 2014 Plan or the Inducement Plan.

Stock Options

The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows:


	Nine Months Ended September 30,
	2022		2021
Estimated fair values of stock options granted	$	0.86	$	3.93
Assumptions:
Risk-free interest rate		1.9% - 3.5%		0.6% - 1.1%
Expected volatility		89.7% - 92.8%		80.1% - 82.0%
Expected term (in years)		5.50 - 6.89		5.5 - 6.5

The Company estimates the fair value of each stock option on the grant date, or other measurement date if applicable, using a Black-Scholes option pricing model, which requires it to make predictive assumptions regarding employee exercise behavior, future stock price volatility, and dividend yield. The Company estimates the risk-free interest rate based on the United States Treasury zero-coupon yield curve at the date of grant for the expected term of the option. The Company estimates its future stock price volatility using the weighted-average historical volatility calculated from a group of comparable public companies over the expected term of the option. The expected term of stock options is estimated using the average of the vesting tranches and the contractual life of each grant for employee options, or the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The use of the simplified method is dependent upon the type of equity award granted and the term of the award. The Company does not pay dividends and does not expect to pay dividends in the foreseeable future.

Option strike prices are set at 100 percent or more of the closing share price on the date of grant and generally vest over three to six years following the grant date. Options generally expire 10 years after the date of grant.

Information on stock option activity is as follows:


	Options Exercisable		Weighted- Average Exercise Price Per Share		Options Outstanding			Weighted- Average Exercise Price Per Share

Balance as of December 31, 2021		2,789,110	$	10.23		4,658,405		$	9.47
Granted		—		—		1,609,000			1.12
Exercised		—		—		—			—
Forfeited or expired		—		—		(420,606	)		7.05

Balance as of September 30, 2022		3,314,828	$	9.88		5,846,799		$	7.35

Stock-based compensation expense related to stock option awards is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
In Thousands	2022		2021		2022		2021
Stock-based compensation expense	$	530	$	698	$	1,420	$	1,103

As of September 30, 2022, options outstanding and exercisable had no aggregate intrinsic value and the weighted average remaining contractual term was 5.3 years as of that date.

Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
In Thousands	2022		2021		2022		2021
Net cash proceeds	$	—	$	—	$	—	$	227

Intrinsic value of options exercised	$	—	$	—	$	—	$	344

As of September 30, 2022, unrecognized compensation expense related to non-vested stock options was $3.7 million. This expense will be recognized over 23 months on average.

Restricted Stock Units

The Company grants restricted stock units which generally vest over three to five years after the date of grant. Information on restricted stock unit activity is as follows:


	Number of Restricted Stock Units Outstanding			Weighted- Average Grant Date Fair Value
Unvested balance as of December 31, 2021		571,303		$	6.15
Granted		1,077,600			1.26
Vested		(274,487	)		6.14
Forfeited		(113,955	)		4.13

Unvested balance as of September 30, 2022		1,260,461		$	2.15

The total grant-date fair value of restricted stock unit awards that vested is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
In Thousands	2022		2021		2022		2021
Grant-date fair value	$	530	$	581	$	1,686	$	1,223

Stock-based compensation expense related to restricted stock units is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
In Thousands	2022		2021		2022		2021
Stock-based compensation expense	$	334	$	416	$	992	$	(105	)

As of September 30, 2022, unrecognized compensation expense related to restricted stock units was $1.6 million. This expense will be recognized over 25 months on average.

The Company accounts for stock-based compensation awards granted to employees of Cellectis as deemed dividends. The Company recorded deemed dividends as follows:


	Three Months Ended September 30,					Nine Months Ended September 30,
In Thousands	2022		2021			2022		2021
Deemed dividends from grants to Cellectis employees	$	18	$	(84	)	$	82	$	(55	)

Performance Stock Units

In June 2022, PSU grants made to two executive officers in 2019 were forfeited because the underlying performance criteria were not met. These PSUs contained a market condition and had a five-year service period. The Company will continue to expense these PSUs over the remaining service period.

In March 2022, the Company granted

530,000

PSUs under the 2017 Plan to five employees including four executive officers. The PSUs include three annual performance periods (2022, 2023, and 2024) and target performance levels for each of those periods linked to the achievement of Company objectives as determined annually for the respective period by the Compensation Committee of the Company’s Board of Directors (the Compensation Committee). Once the annual objectives are approved, the associated expense will be recognized on a straight-line basis over the period from the date of grant through the March 15 determination date. Earned awards will be settled in shares of Company stock no later than the March 15 determination date in the following calendar year. The grant date for the tranche of awards linked to 2022 performance is May 4, 2022. Determination of expense for the 2023 and 2024 tranches of PSUs will be made when the associated business objectives are determined.

In July 2021, the Company granted

600,000

PSUs under the Inducement Plan to Mr. Carr. The PSUs will vest if the Company’s stock remains above three specified price levels for

thirty

calendar days over the

three-year

performance period. The PSUs will be settled in unrestricted shares of the Company’s common stock on the vesting date.

PSU activity for the nine months ended September 30, 2022, is as follows:


	Number of PSUs

Outstanding as of December 31, 2021:		745,000
Issued		530,000
Forfeited/canceled		(145,000	)
Exercised		—

Outstanding as of September 30, 2022:		1,130,000

Stock-based compensation expense related to PSUs is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
In Thousands	2022		2021		2022		2021

Stock-based compensation expense	$	171	$	122	$	478	$	(133	)

As of September 30, 2022, unrecognized compensation expense related to PSUs was $1.1 million. This expense will be recognized over 22 months on average.

6. STOCK-BASED COMPENSATION

On February 19, 2021, James Blome ceased serving as the Company’s Chief Executive Officer. The Company recorded a benefit to earnings from a $2.5 million recapture of

non-cash

stock compensation expense from the forfeiture of Mr. Blome’s unvested stock options, restricted stock units, and performance stock units.

On July 16, 2021, the Company filed a Registration Statement on Form

S-8

with the SEC which registered an additional 4,299,904 shares of common stock that may be issued or delivered and sold pursuant to the 2017 Plan and 600,000 shares of common stock that may be issued or delivered and sold pursuant to the Calyxt, Inc. Employee Inducement Incentive Plan (the Inducement Plan). Shares of common stock are issuable under the Inducement Plan upon the settlement of performance stock units which were granted to Mr. Michael A. Carr in July 2021 as a material inducement to accept employment as the Company’s President and Chief Executive Officer.

As of December 31, 2021, 5,508,797 shares were registered and available for grant under effective registration statements, while 5,642,247 shares were available for grant in the form of stock options, restricted stock, restricted stock units, and performance stock units under the 2017 Plan. Stock-based awards currently outstanding also include awards granted under the 2014 Plan and the Inducement Plan. No further awards will be granted under either the 2014 Plan or the Inducement Plan.

Stock Options

The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows:


	Year ended December 31,
	2021	2020	2019
Estimated fair values of stock options granted	$3.61	$3.24	$10.18
Assumptions:
Risk-free interest rate	0.6% – 1.2%	0.3% –1.7%	1.7% – 2.5%
Expected volatility	80.1% – 91.0%	77.4% –81.2%	52.6% – 78.9%
Expected term (in years)	5.5 – 6.5	6.0 – 10.0	6.8 – 10.0

The Company estimates the fair value of each option on the grant date, or other measurement dates if applicable, using a Black-Scholes option-pricing model, which requires it to make predictive assumptions regarding employee exercise behavior, future stock price volatility, and dividend yield. The Company estimates the risk-

free interest rate based on the United States Treasury

zero-coupon

yield curve at the date of grant for the expected term of the option. The Company estimates its future stock price volatility using the historical volatility of comparable public companies over the expected term of the option. The Company’s expected term represents the period that options granted are expected to be outstanding determined using the simplified method. The Company does not, nor does it expect to, pay dividends.

Information on stock option activity is as follows:


	Options Exercisable		Weighted- Average Exercise Price Per Share		Options Outstanding			Weighted- Average Exercise Price Per Share
Balance as of December 31, 2020		2,347,665	$	10.15		4,621,173		$	10.30
Granted		—		—		774,959			5.20
Exercised		—		—		(61,372	)		3.70
Forfeited or expired		—		—		(676,335	)		10.75

Balance as of December 31, 2021		2,789,110	$	10.23		4,658,425		$	9.47

Stock-based compensation expense related to stock option awards was as follows:


	Year ended December 31,
In Thousands	2021		2020		2019
Stock-based compensation expenses	$	1,850	$	3,371	$	6,035

As of December 31, 2021, options outstanding and exercisable had no aggregate intrinsic value and the weighted average remaining contractual term was 5.6 years as of that date.

Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows:


	Year ended December 31,
In Thousands	2021		2020		2019
Net cash proceeds	$	227	$	212	$	344

Intrinsic value of options exercised	$	344	$	179	$	905

As of December 31, 2021, unrecognized compensation expense related to

non-vested

stock options was $5.2 million. This expense will be recognized over 24 months on average.

Restricted Stock Units

The Company grants restricted stock units which generally vest over three to five years after the date of grant. Information on restricted stock unit activity is as follows:


	Number of Restricted Stock Units Outstanding			Weighted- Average Grant Date Fair Value
Unvested balance at December 31, 2020		547,807		$	9.49
Granted		406,981			4.59
Vested		(193,857	)		7.68
Cancelled		(189,628	)		10.91

Unvested balance at December 31, 2021		571,303		$	6.15

The total grant-date fair value of restricted stock unit awards that vested was as follows:


	Year ended December 31,
In Thousands	2021		2020		2019
Grant-date fair value	$	1,489	$	3,122	$	3,141

Information on the weighted average grant date fair value of restricted stock units issued was as follows:


	Year ended December 31,
In Thousands	2021		2020		2019
Weighted average grant date fair value	$	4.59	$	6.54	$	12.48

Stock-based compensation expense related to restricted stock units was as follows:


	Year ended December 31,
In Thousands	2021		2020		2019
Stock-based compensation expenses	$	224	$	1,155	$	2,910

As of December 31, 2021, unrecognized compensation expense related to restricted stock units was $1.7 million. This expense will be recognized over 22 months on average.

The Company accounts for stock-based compensation awards granted to employees of Cellectis as deemed dividends. The Company recorded deemed dividends as follows:


	Year ended December 31,
In Thousands	2021			2020		2019
Deemed dividends from grants to Cellectis employees	$	(289	)	$	1,168	$	1,358

Performance Stock Units

From

time-to-time,

the Company issues performance stock units to certain individuals in management in order to align their objectives with stockholders of the Company. The Company uses a Monte Carlo simulation pricing model when estimating the fair values of these awards.

2021 Grant

In July 2021, the Company granted 600,000 performance stock units under the Inducement Plan to Mr. Carr. The performance stock units will vest if the Company’s stock remains above three specified price levels for

30 calendar days over the three-year performance period. The performance stock units will be settled in unrestricted shares of the Company’s common stock on the vesting date.

The estimated fair values of performance stock units granted in 2021, and the assumptions used were as follows:


Estimated fair values of performance stock units granted:
At least $12 per share	$	2.16
At least $15 per share	$	1.89
At least $20 per share	$	1.55
Assumptions:
Expected term (in years)		3.0
Expected volatility		90.0	%
Risk-free interest rate		0.4	%

The Company estimated the fair value of each tranche of the performance stock units on the grant date using the Monte Carlo simulation pricing model, which required it to make predictive assumptions as to the expected term of the grant, future stock price volatility, and dividend yield. The expected term represents the expected service period of the performance stock units granted. Expected volatility was based on the historical volatility of the Company’s common stock over the expected term. The Company estimates the risk-free interest rate based on the United States Treasury

zero-coupon

yield curve at the date of grant for the expected term of the option.

2019 Grant

In June 2019, the Company granted 311,667 performance stock units under the 2017 Plan to three executive officers. The performance stock units will vest at 50 percent, 100 percent, or 120 percent of the shares under the award at the end of a three-year performance period based upon increases in the value of the Company’s common stock from the grant price of $12.48. The performance stock units will be settled in restricted stock upon vesting, with restrictions on transfer lapsing on the second anniversary of the restricted stock issuance date. During 2021, the Company recognized a benefit from the forfeiture of 166,667 performance stock units held by Mr. Blome, its former Chief Executive Officer.

The estimated fair values of performance stock units granted, and the assumptions used were as follows:


Estimated fair values of performance stock units granted	$	7.06
Assumptions:
Expected term (in years)		3.0
Expected volatility		75.0	%
Risk-free interest rate		1.71	%

Stock-based compensation expense related to performance stock units is as follows:


	Year ended December 31,
In Thousands	2021		2020		2019
Stock-based compensation expenses	$	16	$	445	$	225

As of December 31, 2021, unrecognized compensation expense related to performance stock units was $1.5 million and will be recognized over 30 months.

Cellectis Equity Incentive Plan

Prior to 2018, Cellectis granted stock options to the Company’s employees. Compensation costs related to these grants have been recognized in the statements of operations with a corresponding credit to stockholders’ equity,

representing the Cellectis’ capital contribution to the Company. The fair value of each stock option was estimated at the grant date using the Black-Scholes option pricing model.

The Company recognized stock-based compensation expense related to its Cellectis’ grants. Expenses in 2019 were immaterial and as of December 31, 2019, all expenses related to these awards had been recognized.

Stock-Based Compensation (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model

The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows:


	Nine Months Ended September 30,
	2022		2021
Estimated fair values of stock options granted	$	0.86	$	3.93
Assumptions:
Risk-free interest rate		1.9% - 3.5%		0.6% - 1.1%
Expected volatility		89.7% - 92.8%		80.1% - 82.0%
Expected term (in years)		5.50 - 6.89		5.5 - 6.5

The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows:


	Year ended December 31,
	2021	2020	2019
Estimated fair values of stock options granted	$3.61	$3.24	$10.18
Assumptions:
Risk-free interest rate	0.6% – 1.2%	0.3% –1.7%	1.7% – 2.5%
Expected volatility	80.1% – 91.0%	77.4% –81.2%	52.6% – 78.9%
Expected term (in years)	5.5 – 6.5	6.0 – 10.0	6.8 – 10.0

Summary of Stock Option Activity

Information on stock option activity is as follows:


	Options Exercisable		Weighted- Average Exercise Price Per Share		Options Outstanding			Weighted- Average Exercise Price Per Share

Balance as of December 31, 2021		2,789,110	$	10.23		4,658,405		$	9.47
Granted		—		—		1,609,000			1.12
Exercised		—		—		—			—
Forfeited or expired		—		—		(420,606	)		7.05

Balance as of September 30, 2022		3,314,828	$	9.88		5,846,799		$	7.35

Information on stock option activity is as follows:


	Options Exercisable		Weighted- Average Exercise Price Per Share		Options Outstanding			Weighted- Average Exercise Price Per Share
Balance as of December 31, 2020		2,347,665	$	10.15		4,621,173		$	10.30
Granted		—		—		774,959			5.20
Exercised		—		—		(61,372	)		3.70
Forfeited or expired		—		—		(676,335	)		10.75

Balance as of December 31, 2021		2,789,110	$	10.23		4,658,425		$	9.47

Summary of Stock-based Compensation Expense

Stock-based compensation expense related to PSUs is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
In Thousands	2022		2021		2022		2021

Stock-based compensation expense	$	171	$	122	$	478	$	(133	)

Schedule of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised

Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
In Thousands	2022		2021		2022		2021
Net cash proceeds	$	—	$	—	$	—	$	227

Intrinsic value of options exercised	$	—	$	—	$	—	$	344

Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows:


	Year ended December 31,
In Thousands	2021		2020		2019
Net cash proceeds	$	227	$	212	$	344

Intrinsic value of options exercised	$	344	$	179	$	905

Summary of Activity of Restricted Stock Units

Information on restricted stock unit activity is as follows:


	Number of Restricted Stock Units Outstanding			Weighted- Average Grant Date Fair Value
Unvested balance as of December 31, 2021		571,303		$	6.15
Granted		1,077,600			1.26
Vested		(274,487	)		6.14
Forfeited		(113,955	)		4.13

Unvested balance as of September 30, 2022		1,260,461		$	2.15

Information on restricted stock unit activity is as follows:


	Number of Restricted Stock Units Outstanding			Weighted- Average Grant Date Fair Value
Unvested balance at December 31, 2020		547,807		$	9.49
Granted		406,981			4.59
Vested		(193,857	)		7.68
Cancelled		(189,628	)		10.91

Unvested balance at December 31, 2021		571,303		$	6.15

Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested

The total grant-date fair value of restricted stock unit awards that vested is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
In Thousands	2022		2021		2022		2021
Grant-date fair value	$	530	$	581	$	1,686	$	1,223

Stock-based compensation expense related to restricted stock units is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
In Thousands	2022		2021		2022		2021
Stock-based compensation expense	$	334	$	416	$	992	$	(105	)

The total grant-date fair value of restricted stock unit awards that vested was as follows:


	Year ended December 31,
In Thousands	2021		2020		2019
Grant-date fair value	$	1,489	$	3,122	$	3,141

Schedule of Weighted Average Grant Date Fair Value of Restricted Stock Units Issued

Information on the weighted average grant date fair value of restricted stock units issued was as follows:


	Year ended December 31,
In Thousands	2021		2020		2019
Weighted average grant date fair value	$	4.59	$	6.54	$	12.48

Summary of Stock-Based Compensation Granted As Deemed Dividends

The Company accounts for stock-based compensation awards granted to employees of Cellectis as deemed dividends. The Company recorded deemed dividends as follows:


	Three Months Ended September 30,					Nine Months Ended September 30,
In Thousands	2022		2021			2022		2021
Deemed dividends from grants to Cellectis employees	$	18	$	(84	)	$	82	$	(55	)

The Company accounts for stock-based compensation awards granted to employees of Cellectis as deemed dividends. The Company recorded deemed dividends as follows:


	Year ended December 31,
In Thousands	2021			2020		2019
Deemed dividends from grants to Cellectis employees	$	(289	)	$	1,168	$	1,358

Share-based Payment Arrangement, Performance Shares, Outstanding Activity

PSU activity for the nine months ended September 30, 2022, is as follows:


	Number of PSUs

Outstanding as of December 31, 2021:		745,000
Issued		530,000
Forfeited/canceled		(145,000	)
Exercised		—

Outstanding as of September 30, 2022:		1,130,000

2021 Grant

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of Fair Values of Performance Stock Units Granted and Assumptions used in Monte Carlo Simulation Pricing Model

The estimated fair values of performance stock units granted in 2021, and the assumptions used were as follows:


Estimated fair values of performance stock units granted:
At least $12 per share	$	2.16
At least $15 per share	$	1.89
At least $20 per share	$	1.55
Assumptions:
Expected term (in years)		3.0
Expected volatility		90.0	%
Risk-free interest rate		0.4	%

2019 Grant

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of Fair Values of Performance Stock Units Granted and Assumptions used in Monte Carlo Simulation Pricing Model

The estimated fair values of performance stock units granted, and the assumptions used were as follows:


Estimated fair values of performance stock units granted	$	7.06
Assumptions:
Expected term (in years)		3.0
Expected volatility		75.0	%
Risk-free interest rate		1.71	%

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of Stock-based Compensation Expense

Stock-based compensation expense related to stock option awards is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
In Thousands	2022		2021		2022		2021
Stock-based compensation expense	$	530	$	698	$	1,420	$	1,103

Stock-based compensation expense related to stock option awards was as follows:


	Year ended December 31,
In Thousands	2021		2020		2019
Stock-based compensation expenses	$	1,850	$	3,371	$	6,035

Restricted Stock Units [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of Stock-based Compensation Expense

Stock-based compensation expense related to restricted stock units was as follows:


	Year ended December 31,
In Thousands	2021		2020		2019
Stock-based compensation expenses	$	224	$	1,155	$	2,910

Performance Stock Units [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of Stock-based Compensation Expense

Stock-based compensation expense related to performance stock units is as follows:


	Year ended December 31,
In Thousands	2021		2020		2019
Stock-based compensation expenses	$	16	$	445	$	225

Stock-Based Compensation - Restricted Stock Units - Additional Information (Detail) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
2017 Omnibus Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
2017 Omnibus Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	6 years
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to restricted stock units	$ 1.6	$ 1.7
Unrecognized stock-based compensation expense, expected recognition weighted-average period	25 months	22 months
Restricted Stock Units [Member] \| 2017 Omnibus Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock Units [Member] \| 2017 Omnibus Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

Stock-Based Compensation - Summary of Activity of Restricted Stock Units (Detail) - Restricted Stock Units [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock units outstanding, Unvested beginning balance	571,303	547,807
Number of restricted stock units outstanding, Granted	1,077,600	406,981
Number of restricted stock units outstanding, Vested	(274,487)	(193,857)
Number of restricted stock units outstanding, Forfeited	(113,955)	(189,628)
Number of restricted stock units outstanding, Unvested ending balance	1,260,461	571,303	547,807
Weighted-average grant date fair value, Unvested beginning balance	$ 6.15	$ 9.49
Weighted-average grant date fair value, Granted	1.26	4.59	$ 6.54	$ 12.48
Weighted-average grant date fair value, Vested	6.14	7.68
Weighted-average grant date fair value, Cancelled	4.13	10.91
Weighted-average grant date fair value, Unvested ending balance	$ 2.15	$ 6.15	$ 9.49

Basis of Presentation & Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Jun. 30, 2022	Jan. 01, 2022	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Year founded		2010
Impairment of long-lived assets	$ 0	$ 0
Operating lease right-of-use assets	13,736	0
Operating lease obligations	13,550	0
Land buildings and equipment and operating lease right of use asset lessee	18,600
Stockholders equity	8,844	$ 14,132	$ 13,759		$ 15,825	$ 21,896	$ 36,875	$ 62,508	$ 93,397
Market capitalization	8,000
Subsidiary [Member]
Property, Plant and Equipment [Line Items]
Percentage of ownership in outstanding common stock		61.80%
Accounting Standards Update 2016-02 [Member]
Property, Plant and Equipment [Line Items]
Operating lease right-of-use assets				$ 14,100
Operating lease obligations				$ 14,100
Stockholders equity cumulative effect of adoption of lease accounting standard.	$ 800
Follow On Offering [Member]
Property, Plant and Equipment [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.41
Date from which Warrants or Rights Exercisable	Aug. 23, 2027

Income Taxes - Summary of Reconciliation of Statutory Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Effective Income Tax Rate Reconciliation, Amount [Abstract]
United States statutory rate	21.00%	21.00%	21.00%
State tax, net of federal benefit	1.00%	4.20%	1.00%
Stock-based compensation	(0.70%)	(0.50%)	(1.60%)
Officer compensation	1.50%	(1.00%)	(1.30%)
Deferred rate change	0.00%	0.00%	0.00%
R&D credit	1.40%	0.80%	1.80%
PPP Loan	1.10%	0.00%	0.00%
Other	0.10%	(0.10%)	0.30%
Change in valuation allowance	(25.40%)	(24.40%)	(21.20%)
Effective income tax rate	0.00%	0.00%	0.00%

Subsequent Event - Additional Information (Detail) $ in Thousands	Nov. 30, 2022 USD ($)
Subsequent Event [Line Items]
Litigation settlement, amount awarded from other party	$ 750
Subsequent Event [Member]
Subsequent Event [Line Items]
Litigation settlement, amount awarded from other party	$ 750

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021	Jul. 16, 2021	Feb. 19, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant	2,712,803	5,508,797
Mr. Blome [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected benefit to earnings from recapture of non-cash stock compensation expense				$ 2.5
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant	3,105,208	5,642,247
Number of common shares available for issue			4,299,904
Calyxt, Inc. Equity Employee Inducement Incentive Plan [Member] \| PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant			600,000

Basis of Presentation & Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Schedule of Estimated Useful Life of Assets Used to Compute Depreciation Using the Straight-line Method

Depreciation is recorded using the straight-line method over estimated useful lives as follows:


Buildings and improvements		10- 20 years
Leasehold improvements		Shorter of lease term or 15 years
Office furniture and equipment		7 years
Assets under capital lease		4 - 20 years
Computer equipment and software		3- 5 years
Vehicles		3- 6 years

Stock-Based Compensation - Summary of Stock-Based Compensation Granted as Deemed Dividends (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Nonemployee Restricted Stock Units [Member] \| Cellectis [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deemed dividends from grants to Cellectis employee	$ 18	$ (84)	$ 82	$ (55)	$ (289)	$ 1,168	$ 1,358

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	ATM Facility Member	Share-based Payment Arrangement [Member]	IPO [Member]	Common Stock [Member]	Common Stock [Member] IPO [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] ATM Facility Member	Additional Paid-In Capital [Member] Share-based Payment Arrangement [Member]	Additional Paid-In Capital [Member] IPO [Member]	Shares in Treasury [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Dec. 31, 2018	$ 93,397				$ 3		$ 176,069				$ (230)	$ (82,445)	$ 0
Beginning balance, shares at Dec. 31, 2018					32,648,893
Net loss	(39,612)											(39,612)
Stock-based compensation	9,175						9,175
Issuance of common stock from stock-based compensation awards,shares					369,260
Issuance of common stock from stock-based compensation awards	344						344
Shares withheld for net share settlement	(813)										(813)
Shares withheld for net share settlement, shares					(66,824)
Other comprehensive income (loss)	17												17
Ending balance at Dec. 31, 2019	62,508				$ 3		185,588				(1,043)	(122,057)	17
Ending balance, shares at Dec. 31, 2019					32,951,329
Net loss	(44,836)											(44,836)
Stock-based compensation	4,971						4,971
Issuance of common stock from stock-based compensation awards,shares					381,507
Issuance of common stock from stock-based compensation awards	212						212
Issuance of common stock	14,037				$ 1		14,036
Issuance of common stock, shares					3,750,000
Shares withheld for net share settlement, shares					(17,792)
Other comprehensive income (loss)	(17)												(17)
Ending balance at Dec. 31, 2020	36,875				$ 4		204,807				(1,043)	(166,893)	0
Ending balance, shares at Dec. 31, 2020					37,065,044
Net loss	(22,142)											(22,142)
Stock-based compensation	865						865
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock units, shares			236,680
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock units, amount			$ 227						$ 227
Ending balance at Sep. 30, 2021	15,825				$ 4		205,899				(1,043)	(189,035)
Ending balance, shares at Sep. 30, 2021					37,301,724
Beginning balance at Dec. 31, 2020	36,875				$ 4		204,807				(1,043)	(166,893)	$ 0
Beginning balance, shares at Dec. 31, 2020					37,065,044
Net loss	(29,199)											(29,199)
Stock-based compensation	2,090						2,090
Issuance of common stock from stock-based compensation awards,shares					270,303
Issuance of common stock from stock-based compensation awards	227						227
Issuance of common stock	4,139						4,139
Issuance of common stock, shares					1,438,647
Ending balance at Dec. 31, 2021	14,132				$ 4		211,263				(1,043)	(196,092)
Ending balance, shares at Dec. 31, 2021					38,773,994
Beginning balance at Jun. 30, 2021	21,896				$ 4		204,663				(1,043)	(181,728)
Beginning balance, shares at Jun. 30, 2021					37,205,473
Net loss	(7,307)											(7,307)
Stock-based compensation	1,236						1,236
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock units, shares			96,251
Ending balance at Sep. 30, 2021	15,825				$ 4		205,899				(1,043)	(189,035)
Ending balance, shares at Sep. 30, 2021					37,301,724
Beginning balance at Dec. 31, 2021	14,132				$ 4		211,263				(1,043)	(196,092)
Beginning balance, shares at Dec. 31, 2021					38,773,994
Net loss	(14,054)											(14,054)
Stock-based compensation	2,890						2,890
Issuance of common stock		$ (7)		$ 5,051		$ 1		$ (7)		$ 5,050
Issuance of common stock, shares				3,880,000
Issuance of common stock upon exercise of pre-funded warrants, shares				3,880,000
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock units, shares			275,274
Cumulative Effect Of Adoption Of Lease Accounting Standard	832											832
Ending balance at Sep. 30, 2022	8,844				$ 5		219,196				(1,043)	(209,314)
Ending balance, shares at Sep. 30, 2022					46,809,268
Beginning balance at Jun. 30, 2022	13,759				$ 5		218,161				(1,043)	(203,364)
Beginning balance, shares at Jun. 30, 2022					46,715,542
Net loss	(5,950)											(5,950)
Stock-based compensation	1,035						1,035
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock units, shares			93,726
Ending balance at Sep. 30, 2022	$ 8,844				$ 5		$ 219,196				$ (1,043)	$ (209,314)
Ending balance, shares at Sep. 30, 2022					46,809,268

Leases, Commitments, and Contingencies - Summary of Future Minimum Rental Payments (Detail) $ in Thousands	Sep. 30, 2022 USD ($)
Schedule of Future Minimum Rental Payments [Abstract]
Operating, Remainder of 2022	$ 345
Operating, 2023	1,446
Operating, 2024	1,480
Operating, 2025	1,479
Operating, 2026	1,479
Operating, 2027	1,479
Operating, Thereafter	16,991
Total Operating	24,699
Operating, Less: imputed interest	(10,814)
Total	13,885
Financing, Remainder of 2022	25
Financing, 2023	100
Financing, 2024	0
Financing, 2025	0
Financing, 2026	0
Financing, 2027	0
Financing, Thereafter	0
Total Financing	125
Financing, Less: imputed interest	(5)
Total	120
Remainder of 2022	370
2023	1,546
2024	1,480
2025	1,479
2026	1,479
2027	1,479
Thereafter	16,991
Total	24,824
Less: imputed interest	(10,819)
Total	$ 14,005

Stock-Based Compensation - Summary of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Net cash proceeds	$ 0	$ 0	$ 0	$ 227	$ 227	$ 212	$ 344
Intrinsic value of options exercised	$ 0	$ 0	$ 0	$ 344	$ 344	$ 179	$ 905

Supplemental Information - Summary of Components of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation Of Revenue [Line Items]
Revenue	$ 42	$ 7,762	$ 115	$ 24,044	$ 25,987	$ 23,851	$ 7,296
Soybean Grain [Member]
Disaggregation Of Revenue [Line Items]
Revenue					25,930	12,976	0
Soybean Meal [Member]
Disaggregation Of Revenue [Line Items]
Revenue					0	8,628	5,604
Soybean Oil [Member]
Disaggregation Of Revenue [Line Items]
Revenue					0	2,220	1,685
Other [Member]
Disaggregation Of Revenue [Line Items]
Revenue					$ 57	$ 27	$ 7

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Leases, Commitments, and Contingencies - Summary of Non Cancellable Operating Leases (Detail) $ in Thousands	Sep. 30, 2022 USD ($)
Disclosure of Non Cancellable Operating Leases [Line Items]
Right-of-Use Asset	$ 13,734
Roseville, MN Lease [Member]
Disclosure of Non Cancellable Operating Leases [Line Items]
Remaining Term (years)	15 years 7 months 6 days
Right-of-Use Asset	$ 13,734

Stockholders' Equity - Summary Of Warrants Transactions (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2022	Feb. 23, 2022
Pre Funded Warrants [Member]
Disclosure of Warrants Transactions [Line Items]
Number of restricted stock units outstanding, Issued	3,880,000
Weighted-average grant date fair value, Issued	$ 0.0001
Number of restricted stock units outstanding, Exercised	3,880,000
Number of restricted stock units outstanding, Unvested ending balance	0
Weighted-average grant date fair value, Unvested ending balance	$ 0
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	0
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0	$ 0.0001
Common Stock Warrants [Member]
Disclosure of Warrants Transactions [Line Items]
Number of restricted stock units outstanding, Issued	7,760,000
Weighted-average grant date fair value, Issued	$ 1.41
Number of restricted stock units outstanding, Unvested ending balance	7,760,000
Weighted-average grant date fair value, Unvested ending balance	$ 1.41
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	7,760,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.41	$ 1.41

Related-Party Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions			9 Months Ended	12 Months Ended
	Feb. 23, 2022	Oct. 20, 2020	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Common stock, issued and sold	3,880,000
Common stock issued price per share	$ 1.41	$ 4			$ 4
Follow-on Public Offering [Member]
Related Party Transaction [Line Items]
Common stock, issued and sold	3,880,000	3,750,000
Common stock issued price per share	$ 1.41
Cellectis [Member]
Related Party Transaction [Line Items]
Minimum net worth required			$ 300.0	$ 300.0
Common stock, issued and sold					1,250,000
Cellectis [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Threshold percentage of ownership in outstanding common stock to enact indemnification agreement			50.00%	50.00%
Cellectis [Member] \| Follow-on Public Offering [Member]
Related Party Transaction [Line Items]
Common stock, issued and sold		1,250,000
Management Fees [Member] \| Cellectis [Member]
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party						$ 1.3

Segment Information	12 Months Ended
Segment Information	Dec. 31, 2021
Segment Reporting [Abstract]
Segment Information	11. SEGMENT INFORMATION The Company operates in a single reportable segment, the development and commercialization of products derived from plant cells. The chief operating decision maker is the Company’s Chief Executive Officer, who makes resource allocation decisions and assesses business performance based on financial information presented on a consolidated basis. There are no segment managers who are held accountable by the chief operating decision maker, or anyone else, for operations, operating results, and planning for levels or components below the consolidated unit level. Accordingly, the Company has determined that it operates in a single reportable segment, the development and commercialization of products derived from plant cells. The Company’s current commercial focus is North America, and all revenue in 2021 was recognized in the United States.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Stock-Based Compensation - Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant-date fair value	$ 530	$ 581	$ 1,686	$ 1,223	$ 1,489	$ 3,122	$ 3,141

Employee Benefit Plan - Additional Information (Detail)	12 Months Ended
Employee Benefit Plan - Additional Information (Detail)	Dec. 31, 2021
Compensation Related Costs [Abstract]
Defined contribution plan description	The Company provides a 401(k) defined contribution plan for all regular full-time employees who have completed two months of service.

Stock-Based Compensation - Schedule of Weighted Average Grant Date Fair Value of Restricted Stock Units Issued (Detail) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value, Granted	$ 1.26	$ 4.59	$ 6.54	$ 12.48

Stock-Based Compensation - Performance Stock Units - Additional Information (Detail) $ / shares in Units, $ in Millions	1 Months Ended		9 Months Ended	12 Months Ended
	Jul. 31, 2021 Day shares	Jun. 30, 2019 $ / shares shares	Sep. 30, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Jul. 07, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted			2,712,803	5,508,797
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted			3,105,208	5,642,247
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to performance stock units \| $			$ 1.1	$ 1.5
Unrecognized stock-based compensation expense, expected recognition weighted-average period			22 months	30 months
Performance Stock Units [Member] \| 2021 Grant \| Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Consecutive trading day \| Day	30
Performance Stock Units [Member] \| 2021 Grant \| Mr Carr [Member] \| 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted			530,000
Performance Stock Units [Member] \| 2021 Grant \| Mr Carr [Member] \| Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted	600,000				600,000
Performance Stock Units [Member] \| 2019 Grant \| 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Increase in common stock starting price \| $ / shares		$ 12.48
Performance Stock Units [Member] \| 2019 Grant \| Tranche One [Member] \| 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		50.00%
Performance Stock Units [Member] \| 2019 Grant \| Tranche Two [Member] \| 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		100.00%
Performance Stock Units [Member] \| 2019 Grant \| Tranche Three [Member] \| 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		120.00%
Performance Stock Units [Member] \| 2019 Grant \| Three Executive Officers [Member] \| 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted		311,667
Performance Stock Units [Member] \| 2019 Grant \| Mr. Blome [Member] \| 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Benefit from forfeiture of stock				166,667

Going Concern - Additional Information (Details) - USD ($)			3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 03, 2022	Feb. 23, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2022	Dec. 31, 2018
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net loss			$ (5,950,000)	$ (7,307,000)	$ (14,054,000)	$ (22,142,000)	$ (29,199,000)	$ (44,836,000)	$ (39,612,000)
Net cash used by operating activities					(15,601,000)	(14,654,000)	(18,811,000)	(43,672,000)	(31,951,000)
Cash, cash equivalents, and restricted cash			7,205,000	$ 14,913,000	7,205,000	$ 14,913,000	14,421,000	18,289,000	60,038,000		$ 95,288,000
Restricted cash							499,000	393,000	$ 388,000
Cash expense for separation-related payments			174,000		174,000		499,000	393,000		$ 100,000
Current liabilities			4,228,000		4,228,000		4,854,000	6,945,000
Common stock, issued and sold		3,880,000
Issuance of common stock		$ 10,000,000					4,139,000	$ 14,037,000
After deduction of underwriting discounts and estimated other offering expenses		$ 900,000
ATM Facility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential cash inflow from the offer of shares					100,000
Shelf Registration Statement [Member] \| ATM Facility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Minimum public float			75,000,000		$ 75,000,000		$ 75,000,000
Cellectis [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, issued and sold								1,250,000
Maximum [Member] \| Cellectis [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Threshold percentage of ownership in outstanding common stock to enact indemnification agreement					50.00%		50.00%
Pre-funded Warrants [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants issued (in shares)		3,880,000
Common Warrants [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants issued (in shares)		7,760,000
Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, issued and sold		3,880,000
Issuance of common stock		$ 10,000,000
After deduction of underwriting discounts and estimated other offering expenses		$ 900,000
Subsequent Event [Member] \| ATM Facility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, issued and sold	2,000,000
After deduction of underwriting discounts and estimated other offering expenses	$ 100,000
Subsequent Event [Member] \| Maximum [Member] \| ATM Facility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock shares subscribed but not issued	15,661,000
Subsequent Event [Member] \| Pre-funded Warrants [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants issued (in shares)		3,880,000
Subsequent Event [Member] \| Common Warrants [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants issued (in shares)		7,760,000
Forecast [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash expense for separation-related payments										$ 500,000
Equipment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Restricted cash			$ 200,000		$ 200,000		$ 600,000

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 7,031	$ 13,823	$ 17,299
Short-term investments		0	11,698
Restricted cash	174	499	393
Accounts receivable		0	4,887
Inventory		0	1,383
Prepaid expenses and other current assets	739	859	3,930
Total current assets	7,944	15,181	39,590
Non-current restricted cash	0	99	597
Land, buildings, and equipment	4,859	21,731	22,860
Operating lease right-of-use assets	13,736	0
Other non-current assets	163	183	280
Total assets	26,702	37,194	63,327
Current liabilities:
Accounts payable	435	1,260	929
Accrued expenses	380	339	2,891
Accrued compensation	2,356	2,522	1,950
Due to related parties	138	172	766
Current portion of financing lease obligations	120	370	364
Common stock warrants	402	0
Other current liabilities	397	191	45
Total current liabilities	4,228	4,854	6,945
Financing lease obligations	0	17,506	17,876
Operating lease obligations	13,550	0
Long-term debt		0	1,518
Other non-current liabilities	80	702	113
Total liabilities	17,858	23,062	26,452
Stockholders' equity:
Common stock value	5	4	4
Additional paid-in capital	219,196	211,263	204,807
Common stock in treasury	(1,043)	(1,043)	(1,043)
Accumulated deficit	(209,314)	(196,092)	(166,893)
Total stockholders' equity	8,844	14,132	36,875
Total liabilities and stockholders' equity	$ 26,702	$ 37,194	$ 63,327

Stock-Based Compensation - Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model (Detail) - Stock Options [Member] - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair values of stock options granted	$ 0.86	$ 3.93	$ 3.61	$ 3.24	$ 10.18
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.90%	0.60%	0.60%	0.30%	1.70%
Expected volatility	89.70%	80.10%	80.10%	77.40%	52.60%
Expected term (in years)	5 years 6 months	5 years 6 months	5 years 6 months	6 years	6 years 9 months 18 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	3.50%	1.10%	1.20%	1.70%	2.50%
Expected volatility	92.80%	82.00%	91.00%	81.20%	78.90%
Expected term (in years)	6 years 10 months 20 days	6 years 6 months	6 years 6 months	10 years	10 years

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended	12 Months Ended
	Oct. 03, 2022	Feb. 23, 2022	Oct. 20, 2020	Jan. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2022
Equity, Class of Treasury Stock [Line Items]
Preferred stock share authorized					50,000,000
Preferred stock share par value					$ 0.0001
Common stock, issued and sold		3,880,000
Common stock issued price per share		$ 1.41	$ 4			$ 4
Net proceeds from issuance of common stock and exercise of overallotment		$ 10,000			$ 4,139	$ 14,037
After deduction of underwriting discounts and estimated other offering expenses		$ 900
Repurchase of Common Stock							$ 800
Common stock, shares issued					38,874,146	37,165,196		46,909,420
Proceeds from common stock issuance					$ 4,380	$ 15,000	$ 0
ATM Facility [Member]
Equity, Class of Treasury Stock [Line Items]
Aggregate common stock offering value					$ 50,000
Common stock, shares issued					1,400,000
Proceeds from common stock issuance					$ 3,900
Pre-funded Warrants [Member]
Equity, Class of Treasury Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.0001						$ 0
Pre-funded Warrants [Member] \| Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)		3,880,000
Common Warrants [Member] \| Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)		7,760,000
Common Stock Warrants [Member]
Equity, Class of Treasury Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.41						$ 1.41
Common Stock, Voting Rights		4.99
Common Stock Warrants [Member] \| Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Date from which Warrants or Rights Exercisable		Aug. 23, 2027
Common Stock Warrants [Member] \| Minimum [Member]
Equity, Class of Treasury Stock [Line Items]
Date from which Warrants or Rights Exercisable		Aug. 23, 2022
Subsequent Event [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock, issued and sold		3,880,000
Net proceeds from issuance of common stock and exercise of overallotment		$ 10,000
After deduction of underwriting discounts and estimated other offering expenses		$ 900
Subsequent Event [Member] \| ATM Facility [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock, issued and sold	2,000,000
After deduction of underwriting discounts and estimated other offering expenses	$ 100
Proceeds from common stock issuance				$ 200
Subsequent Event [Member] \| ATM Facility [Member] \| Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock shares subscribed but not issued	15,661,000
Subsequent Event [Member] \| Pre-funded Warrants [Member] \| Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)		3,880,000
Subsequent Event [Member] \| Common Warrants [Member] \| Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)		7,760,000
Cellectis [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock, issued and sold						1,250,000
Follow-on Public Offering [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock, issued and sold		3,880,000	3,750,000
Common stock issued price per share		$ 1.41
Net proceeds from issuance of common stock and exercise of overallotment		$ 10,000	$ 14,000
Underwriting discounts and commissions			$ 1,000
After deduction of underwriting discounts and estimated other offering expenses		$ 900
Follow-on Public Offering [Member] \| Pre-funded Warrants [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock issued price per share		$ 1.4099
Follow-on Public Offering [Member] \| Pre-funded Warrants [Member] \| Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)		3,880,000
Follow-on Public Offering [Member] \| Common Warrants [Member] \| Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)		7,760,000
Follow-on Public Offering [Member] \| Subsequent Event [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock, issued and sold		3,880,000
Net proceeds from issuance of common stock and exercise of overallotment		$ 10,000
After deduction of underwriting discounts and estimated other offering expenses		$ 900
Follow-on Public Offering [Member] \| Subsequent Event [Member] \| Pre-funded Warrants [Member] \| Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)		3,880,000
Follow-on Public Offering [Member] \| Subsequent Event [Member] \| Common Warrants [Member] \| Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)		7,760,000
Follow-on Public Offering [Member] \| Cellectis [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock, issued and sold			1,250,000
Net proceeds from issuance of common stock and exercise of overallotment			$ 5,000
Outstanding obligation paid to parent			$ 14,000

Segment Information - Additional Information (Detail)	12 Months Ended
Segment Information - Additional Information (Detail)	Dec. 31, 2021 Segment
Segment Reporting [Abstract]
Number of reportable segments	1

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2022	Dec. 31, 2019
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair value of financing leases	$ 14,500	$ 15,200
Short-term investments	0	11,698		$ 0
Commodity Contract [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Commodity derivative assets, notional amount		12,800
Unrealized commodity derivative losses from hedging contracts sold	0	$ (2,000)
Corporate Debt Securities [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Short-term investments	$ 0
Other Financial Instruments			$ 0

Financial instruments and financial risk management - Summary of Fair Value of the Common Warrants (Details)	Sep. 30, 2022 yr
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated fair value of Common Warrants	0.05
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumptions	4.1
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumptions	85
Expected term to liquidation (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumptions	4.9

Basis of Presentation & Summary of Significant Accounting Policies

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

Accounting Policies [Abstract]

Basis of Presentation & Summary of Significant Accounting Policies

1. BASIS OF PRESENTATION & SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The unaudited consolidated financial statements of Calyxt, Inc. (Calyxt or the Company) have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP or GAAP) for interim financial information and with the rules and regulations of the Securities and Exchange Commission (SEC) applicable to interim financial statements. In the Company’s opinion, the accompanying consolidated financial statements reflect all adjustments necessary for a fair presentation of its statements of financial position, results of operations, and cash flows for the periods presented but they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Except as otherwise disclosed herein, these adjustments consist of normal recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole or any other interim period.

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the consolidated financial statements and during the reporting period. Actual results could materially differ from these estimates.

Certain prior year amounts have been reclassified to conform to the current year presentation.

For further information, refer to the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 3, 2022. The accompanying Balance Sheet as of December 31, 2021, was derived from the audited consolidated financial statements. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes included in the Annual Report on Form 10-K for the year ended December 31, 2021.

Net Loss Per Share

Due to the Company’s net loss position for the three and nine months ended September 30, 2022, and September 30, 2021, all of its outstanding stock options, restricted stock units (RSUs), performance stock units (PSUs), and warrants to purchase common stock (Common Warrants) are considered anti-dilutive and excluded from the calculation of net loss per share. Accordingly, the treasury method was not used in determining the number of anti-dilutive stock options, RSUs, PSUs, or Common Warrants.

Warrants

The Company issued pre-funded warrants to purchase common stock (Pre-Funded Warrants) in a follow-on offering on February 23, 2022 (the Follow-On Offering). The Pre-Funded Warrants were exercised in full on May 4, 2022, and subsequently settled with the counterparty.

The Company also issued Common Warrants in the Follow-On Offering. The Common Warrants expire on August 23, 2027 and are exercisable for one share of the Company’s common stock for $1.41 per share. The Common Warrants have been classified as a liability because they include a put option election available to their holder that is contingently exercisable if the Company enters into a fundamental transaction (Fundamental Transaction), generally described as a “change of control” (the Change of Control Put). If the Change of Control Put is exercised by the holder of a Common Warrant, they may elect to receive either the consideration of the Fundamental Transaction or put the Common Warrant back to the Company in exchange for cash, based on terms and timing specified in the Common Warrant agreement. If the Change of Control Put option is exercised, the Company is required to pay cash to the holder in an amount as determined by the Black Scholes pricing model, with assumptions determined in accordance with the terms of the Common Warrants.

The Common Warrants are reported at fair value with changes in fair value reported in earnings. The Company reports the changes in fair value of the Common Warrants in non-operating income (expenses) in its consolidated statements of operations.

Impairment of Long-Lived Ass

ets

As of September 30, 2022, the Company had $18.6 million of land, buildings, and equipment and operating lease right-of-use assets and a net book value of $8.8 million. As of September 30, 2022, the Company’s market capitalization was $8.0 million. The Company has a single asset group and reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of that asset group may not be recoverable. One such impairment indicator is if the Company’s market capitalization is lower than its net book value for an extended period of time.

If the impairment tests indicate that the carrying value of the asset group is greater than the expected undiscounted cash flows to be generated by the asset group, further analysis is performed to determine the fair value of the asset group. To the extent the fair value of the asset group is less than its carrying value, an impairment loss is recognized equal to the amount the carrying value exceeds the fair value of the asset group. Fair value is measured using a discounted cash flow model or independent appraisals, as appropriate.

As of the date of this filing, management has determined there was no impairment of its long-lived assets based on its financial projections and its stated pursuit of strategic alternatives, which could include various outcomes.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) and in July 2018, ASU No. 2018-10, Codification Improvements to Topic 842, Leases, and ASU 2018-11, Leases (Topic 842) – Targeted Improvements (collectively, the Standard). The Standard requires lessees to record assets and liabilities on the balance sheet for all leases with terms longer than 12 months. The Standard establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement.

The Company adopted the Standard as of January 1, 2022, using the transition method which does not require revisions to comparative periods. The Company elected to implement the transition package of practical expedients permitted within the Standard, which among other things, allows it to carryforward the historical lease classification. In addition, the Company elected the hindsight practical expedient to determine the lease term for existing leases and it also made an accounting policy election to not record leases with an initial term of 12 months or less on its consolidated balance sheet.

The Company’s adoption of the Standard required it to remove the previously reported amounts for land, buildings, and equipment associated with its headquarters and laboratory facility lease as well as the associated liability. The Company assessed the elements of its lease agreement and upon adoption, recorded an operating lease associated with the sale leaseback of land component of the lease, and a second operating lease associated with the building component of the lease. The Company recorded operating lease assets and liabilities of $14.1 million within its consolidated balance sheet as of January 1, 2022. The Standard had no impact on the Company’s consolidated statements of operations or cash flows. The $0.8 million cumulative effect of the adoption of the Standard was recorded to stockholders’ equity. See Note 8 for further information regarding the Company’s leases.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326)” (ASU 2016-13). ASU 2016-13 creates accounting requirements on how to account for credit losses on most financial assets and certain other instruments. This will require the estimation of lifetime expected credit losses and

corresponding recognition of allowance for losses on trade and

other receivables

, loans, and other instruments held at amortized cost. The ASU requires certain recurring disclosures and is effective for annual periods, and interim periods within those annual periods, beginning on or after December 15, 2023. The Company is in the process of analyzing the impact of this standard on its results of operations.

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Overview

Calyxt, Inc. was founded in 2010

and incorporated in Delaware. Calyxt is a plant-based synthetic biology company that leverages its proprietary PlantSpring

™

technology platform to engineer plant metabolism to produce innovative, high-value materials and products for use in helping customers meet their sustainability targets and financial goals. The Company is focused on developing these materials and products for customers in large and differentiated end markets including the cosmeceutical, nutraceutical, and pharmaceutical industries. The Company uses its PlantSpring technology platform for development of those plant-based chemistries and will produce them in its proprietary BioFactory

production system.

Prior to its initial public offering (IPO) on July 25, 2017, the Company was a wholly owned subsidiary of Cellectis S.A. (Cellectis). As of December 31, 2021, Cellectis owned

61.8

percent of the Company’s issued and outstanding common stock. Cellectis has certain contractual rights as well as rights pursuant to the Company’s certificate of incorporation and bylaws, in each case, for so long as it maintains threshold beneficial ownership levels in the Company’s shares.

Basis of Presentation and Use of Estimates

The Company has prepared its Consolidated Financial Statements according to accounting principles generally accepted in the United States and has included the accounts of Calyxt and its subsidiary.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes, including those related to revenue recognition, the net realizable value of inventories, stock-based compensation, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.

Cash, Cash Equivalents, Restricted Cash, and Investments

All investments purchased with an original maturity of three months or less are accounted for as cash equivalents. The Company’s restricted cash balances are cash and cash equivalents deposited in an amount equal to the future rent payments as required under the Company’s equipment lease facility. The Company may request the return of excess restricted cash collateral annually in December. The amount of the restricted cash balance the Company expects to have returned in December 2022 is reflected as a current asset.

The Company periodically invests its cash in high grade, highly liquid securities, and investment funds. The Company considers securities purchased with more than ninety days to their original maturity at issuance to be short-term investments. These short-term investments are classified as

available-for-sale

securities based on the Company’s intent to generally match maturities with Calyxt’s projected monthly cash usage. The Company held these securities to their planned maturity or liquidated them earlier in response to variations in the Company’s monthly cash usage.

The Company ensures the credit risk in this portfolio is in accordance with its internal policies and if necessary, makes changes to investments to ensure credit risk is minimized. The Company has not experienced any counterparty credit losses.

Accounts Receivable

Accounts receivable are unsecured and are recorded at net realizable value. The Company makes judgments as to its ability to collect outstanding receivables based upon patterns of collectability, historical experience, and its

evaluation of specific accounts and will provide an allowance for credit losses when collection becomes doubtful. The Company performs credit evaluations of its customers’ financial condition on an

as-needed

basis. Payment is generally due fifteen or thirty days from the invoice date depending upon the product, and accounts pa

st 30

days are individually analyzed for collectability. When all collection efforts have been exhausted, the account is written off.

Inventory

Inventories are recorded at the lower of cost or net realizable value and include all costs of seed production and grain the Company purchased as well as costs to store and transport the grain. As of December 31, 2020, inventory included the costs to process the grain into finished products. Consideration received from growers when they purchase seed is recorded as a reduction of inventory.

The Company evaluates inventory balances for obsolescence or estimated net realizable value on a regular basis based on the age of the inventory and its sales forecasts. At each

period-end,

the Company made assumptions regarding projected selling prices for its products considering futures market prices for the underlying agricultural markets and its associated risk management strategies, anticipated costs, and other factors that take into consideration its limited operating history and compare those prices to the current weighted average inventory costs. If the Company’s costs were higher than the projected selling prices, then a valuation adjustment was recorded.

Prior to the commercialization of its high oleic soybean products, the Company expensed all grain costs as R&D.

Forward Purchase Contracts

Under the Company’s former

go-to-market

soybean strategy, it would enter into hedging contracts to convert fixed price grain inventories and fixed price grain production agreements to floating prices, consistent with how the grain was sold.

The seed contracts often required the Company to pay prices for the seed produced at commodity futures market prices plus a premium. The seed growers had the option to fix their price with the Company throughout the term of the agreement. The Company paid a portion of the seed cost in December each year and the remainder upon delivery in either the first or second quarter of the following year.

The grain grower contracts required the Company to pay prices for all grain produced at commodity futures market prices plus a premium. The grain growers had the option to fix their price with the Company throughout the term of the agreement. The grain grower contracts allowed for delivery of grain to the Company at harvest, if so specified when the agreement was executed, otherwise delivery occurred on a date that was elected by the Company through August 31, 2021. The Company paid for grain within a contractually determined number of days following delivery and final pricing.

Upon delivery, the inventory was carried at historical cost but sold at prevailing market prices. As a result, the Company entered into hedging arrangements by selling futures contracts which converted its market exposure to these fixed prices to floating prices. By executing these hedging strategies, the Company could closely match the expected economic terms of the grain sale with the market, which helped stabilize margins until such inventory was sold. The Company did not account for these economic hedges as accounting hedges. All unrealized gains or losses on outstanding hedging contracts were recognized in Cost of Goods sold. The Company expected that any gains or losses from these hedging arrangements would be offset by gains or losses on the grain inventories when such grain inventories were sold.

Prior to August 1, 2020, the Company designated all of its commodity derivative contracts as cash flow hedges based on the nature of its business activities. As a result, all gains or losses associated with recording those

commodity derivative contracts at fair value were recorded as a component of accumulated other comprehensive income (loss) (AOCI). The Company reclassified amounts from AOCI to cost of goods sold when the underlying products were sold to which those hedges related. For the year ended December 31, 2020, the Company reclassified a nominal amount from AOCI to cost of goods sold, and there were no such reclassifications in 2021.

Land, Buildings, and Equipment

Land, buildings, and equipment are stated at cost less accumulated depreciation. Assets under capital lease are stated at the lesser of their net present value of future lease payments or fair market value. Repairs and maintenance costs are expensed as incurred. The cost and accumulated depreciation of property and equipment retired, or otherwise disposed of, are removed from the related accounts, and any residual values are charged to expense. Depreciation is recorded using the straight-line method over estimated useful lives as follows:


Buildings and improvements		10- 20 years
Leasehold improvements		Shorter of lease term or 15 years
Office furniture and equipment		7 years
Assets under capital lease		4 - 20 years
Computer equipment and software		3- 5 years
Vehicles		3- 6 years

Impairment of Long-Lived Assets

The Company has a single asset group and reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of that asset group may not be recoverable. If the impairment tests indicate that the carrying value of the asset group is greater than the expected undiscounted cash flows to be generated by the asset group, further analysis is performed to determine the fair value of the asset group. To the extent the fair value of the asset group is less than its carrying value, an impairment loss is recognized equal to the amount the carrying value exceeds the fair value of the asset group. If the Company’s plans or intentions change with regard to a specific asset within the asset group, that asset’s remaining useful life is assessed and depreciation is accelerated if necessary. Assets to be disposed of are carried at the lower of their carrying value or fair value less costs to sell. Fair value is measured using a discounted cash flow model or independent appraisals, as appropriate. The Company has not recognized any impairment losses in these consolidated financial statements.

Revenue Recognition

The Company accounts for a contract as revenue when it has approval and commitment to perform from both parties, the rights of the parties are identified, payment terms are established, the contract has commercial substance, and collectability of the consideration is probable. Changes to contracts are assessed for whether they represent a modification or should be accounted for as a new contract. The Company considers the following indicators, among others, when determining if it is acting as a principal in the transaction and recording revenue on a gross basis: (i) the Company is primarily responsible for fulfilling the promise to provide the specified good or service, (ii) the Company has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer and (iii) the Company has discretion in establishing the price for the specified good or service. If a transaction does not meet the Company’s indicators of being a principal in the transaction, then the Company is acting as an agent in the transaction and the associated revenues are recognized on a net basis.

The Company recognizes revenue when control of the good or service has passed to the customer. The following indicators are evaluated in determining when control has passed to the customer: (i) the customer has legal title to the product, (ii) the Company has transferred physical possession of the product or service to the customer,

(iii) the Company has a right to receive payment for the good or service, (iv) the customer absorbs the significant risks and rewards of ownership of the good and (v) the customer has accepted the good.

The Company generally does not incur costs to obtain new contracts.

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s contracts may contain multiple performance obligations if a promise to transfer the individual good or service is separately identifiable from other promises in the contracts and, therefore, is considered distinct. Performance obligations that are not considered distinct are combined with other goods or services in the contract until that combination meets the distinct criteria above. For contracts with multiple performance obligations, the Company determines the standalone selling price of each performance obligation and allocates the total transaction price using the relative selling price basis.

The following is a description of the principal goods and services from which the Company generates revenue:

Product Sales

Historically, the Company sold soybean grain, oil, and meal. The Company recognized sales revenue at the point in time that title transferred to the customer, which was based on shipping terms. Sales included shipping and handling charges if billed to the customer and were reported net of trade promotion and other costs, including estimated allowances for returns, unsalable product, and prompt pay discounts. Sales, use, value-added, and other excise taxes were not recognized in revenue. Trade promotions were recorded based on estimated participation and performance levels for offered programs at the time of sale. The Company generally did not allow a right of return.

During 2021 and 2020, the Company sold soybean grain to a processor and subsequent to the sale they utilized the Company’s rented third-party storage facility to hold the grain until such time they requested it be delivered. The Company was responsible for all handling charges and delivery activities. In those instances, the Company recognized revenue from the sale of grain to the processor upon the transfer of the control of the grain, which was determined to be at the time of the issuance of the purchase order and assignment of warehouse receipts to the customer. The Company determined that the reason for the arrangement was substantive, in that the customer had requested the arrangement, the product was separately identified as belonging to the customer, the product was ready for physical transfer, and the Company did not have the ability to use the product or direct it to another customer. The Company concluded that any remaining performance obligations (e.g., for custodial services) were immaterial in relation to the contract. The Company concurrently accrued all estimated future storage, handling, and delivery costs associated with that sale. All arrangements of this nature were completed prior to December 31, 2021.

In certain transactions occurring in the third quarter of 2020, the Company sold grain to a processor with a commitment to provide consideration to the processor in exchange for the soybean meal resulting from the grain crushing activity. The Company determined the consideration payable to the processor was not in exchange for a distinct good or service, as the soybean meal was considered highly interrelated to the grain because they both possess Calyxt specific genetic traits, and the transactions were entered into in contemplation of one another, and therefore, were not considered to be distinct within the context of the contract. For these transactions, the Company recognized revenue from the sale of grain in the amount of the final net cash settlement with the processor, as the consideration payable to the processor was treated as a reduction of revenue.

Technology Licensing

The Company recognizes revenue from license agreements, which may consist of nonrefundable

up-front

payments, milestone payments, annual licensing fee payments, royalty payments, and payments for services.

Nonrefundable

up-front

payments are deferred and recognized as revenue over the term of the license agreement. If a license agreement is terminated before the original term of the agreement is fulfilled, all remaining deferred revenue is recognized at termination.

Annual licensing fee payments are generally associated with services in the contract and are recognized over time as the customer receives the benefits of the services. If necessary, the Company establishes and increases a contract asset as the revenue is recognized. For these types of payments, the Company recognizes revenue using an input method, such as the completed contract or time elapsed methods, or an output method, such as the work performed or units produced methods. The Company will apply each method of revenue recognition consistently for like contracts and assess any revenue estimates periodically for cumulative adjustments.

In certain instances, the receipt of payments in these arrangements are dependent upon the achievement of certain scientific, regulatory, commercial, or other milestones. The Company recognizes milestone payments when the triggering event has occurred, there are no further contingencies or services to be provided with respect to that event, and the counterparty has no right to refund of the payment.

Royalty revenues are expected to arise following the commercialization of products developed using the licensed technology by the counterparty to the license agreement. The royalties may be a percentage of sales or another measurement achieved by the licensee. Royalty revenues will be recognized at the later of (i) when the licensee is generating sales subject to royalty payments or (ii) the performance obligation to which the sales-based or usage-based royalties relates has been satisfied.

Product Development Agreements

The Company recognizes revenue from product development agreements, which may consist of nonrefundable

up-front

payments, milestone payments, annual payments, and payments for services.

Nonrefundable

up-front

payments are recognized as revenue over the term of the development agreement. If a development agreement is terminated before the original term of the agreement is fulfilled, all remaining deferred revenue is recognized at termination.

In certain instances, the receipt of payments in these arrangements are dependent upon the achievement of certain scientific, regulatory, commercial, or other milestones. Milestone payments are considered variable consideration which are evaluated against the Company’s performance obligations for determination of when it is appropriate to recognize revenue. For purposes of revenue recognition, the Company considers whether the performance obligation is achieved, which may be (i) when a triggering event has occurred, (ii) there are no further contingencies or services to be provided with respect to that event, and (iii) the customer has no right to require refund of their payment. The Company recognizes milestone payments as revenue when it is highly probable that any revenue recognized will not be subsequently reversed.

Annual payments are generally associated with services in the contract and are recognized over time as the customer receives the benefits of the services. If necessary, the Company establishes and increases a contract asset as the revenue is recognized. For these types of payments, the Company recognizes revenue using an input method, such as the completed contract or time elapsed methods, or an output method, such as the work performed or units produced methods. The Company will apply each method of revenue recognition consistently for like contracts and assess any revenue estimates periodically for cumulative adjustments.

Agreements for the performance of research and development services and cost reimbursements are recognized as revenue over time based on work performed.

Collaborative Arrangements

For arrangements that do not represent contracts with a customer, the Company analyzes the transaction to assess whether the arrangement involves joint operating activities performed by parties that are both active participants

in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. The Company had no such arrangements as of December 31, 2021.

Advertising Costs

The Company expenses advertising costs as incurred.

Research and Development Expenses

The Company recognizes R&D expenses as incurred. These expenses consist of direct costs for R&D and

R&D-related

allocations of overhead costs such as facilities and information technology costs. Costs incurred in connection wit

h customer-fun

ded activities are expensed as incurred. Costs to acquire technologies that are utilized in R&D that have no alternative future use are expensed as incurred. Prior to the commercialization of the Company’s soybean product, the Company expensed all grain costs as R&D.

Patents

The Company expenses patent costs, including related legal costs, as incurred. Costs to write and support the research for filing patents are recorded as R&D expenses in the statements of operations. Costs to maintain,

in-license,

and defend patents are recorded as SG&A expenses in the statements of operations.

Stock-Based Compensation

The Company generally measures the fair value of employee and nonemployee stock-based awards on their grant date and records compensation expense on a straight-line basis over the related service period of the award, which is generally the vesting period. The Company uses the Black-Scholes option pricing model to value its stock option awards. The Company generally measures compensation expense for grants of restricted stock units using the Company’s share price on the date of grant. The Company uses a Monte Carlo simulation pricing model when estimating the fair values of performance stock units. The Company estimates fair values and accounts for employee and nonemployee awards in a similar manner.

Due to the Company’s limited history, it does not always have sufficient historical stock option activity to make predictive assumptions based solely on its stock or stock option activity for the Black-Scholes option pricing model. As a result, the Company may need to use data from other comparable public companies or alternative calculation methods to make predictive assumptions.

The Company estimates its future stock price volatility using the weighted-average historical volatility calculated from a group of comparable public companies over the expected term of the option. The group of comparable public companies is determined by management on an annual basis. When selecting a comparable company, management considers relevant factors including industry and strategy, size, maturity, and financial leverage. The comparable companies used by management to calculate expected volatility may change from

year-to-year

because of changes in those factors and because a new comparable company may become publicly traded.

The expected term of stock options is estimated using the average of the vesting tranches and the contractual life of each grant for employee options, or the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.

Due to the limited historical experience of the Company’s stock awards program, it has elected to account for forfeitures of awards as they occur. If an award is forfeited prior to vesting, the associated reduction in expense is reflected net in stock-based compensation expense in that period. Stock-based compensation expense is recorded in R&D and SG&A expenses in the Company’s consolidated statements of operations.

Income Taxes

Current income taxes are recorded based on statutory obligations for the current operating period for the jurisdictions in which the Company has operations.

Deferred taxes are provided on an asset and liability method, whereby deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when the Company believes it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Foreign Currency Transactions

Transactions in foreign currencies are translated at the exchange rates effective on the transaction dates. Assets and liabilities denominated in foreign currencies are translated at the

period-end

exchange rate. Foreign currency gains and losses are recognized in

non-operating

expenses in the consolidated statements of operations.

Foreign currency fluctuations affect the Company’s foreign currency cash flows related primarily to payments to Cellectis. The Company’s principal foreign currency exposure is to the euro. The Company does not hedge these exposures, and it does not believe that the current level of foreign currency risk is significant to its operations.

Net Loss Per Share

Due to the Company’s net loss position for the years ended December 31, 2021, 2020, and 2019, all its outstanding stock options, restricted stock units, and performance stock units are considered anti-dilutive and excluded from the calculation of net loss per share. Accordingly, the treasury method was not used in determining the number of anti-dilutive stock options and restricted stock units.

Recently Issued Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU)

No. 2016-02,

“Leases (Topic 842)” (ASU

2016-02).

Under ASU

2016-02,

an entity will be required to recognize assets and liabilities for the rights and obligations created by leases on the entity’s balance sheet for both finance and operating leases. For leases with a term of 12 months or less, an entity can elect to not recognize lease assets and lease liabilities and expense the lease over a straight-line basis for the term of the lease. Because the Company is an emerging growth company, the Company adopted the new standard on January 1, 2022, using the cumulative effect upon adoption approach.

In June 2016, the FASB issued ASU

No. 2016-13,

“Financial Instruments – Credit Losses (Topic 326)” (ASU

2016-13).

ASU

2016-13

creates accounting requirements on how to account for credit losses on most financial assets and certain other instruments. This will require the estimation of lifetime expected credit losses and corresponding recognition of allowance for losses on trade and other receivables, loans, and other instruments held at amortized cost. The ASU requires certain recurring disclosures and is effective for annual periods, and interim periods within those annual periods, beginning on or after December 15, 2023. The Company is analyzing the impact of this standard on its results of operations and financial position.

Supplemental Information - Summary of Certain Statements of Operations Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expenses	$ 1,035	$ 1,236	$ 2,890	$ 865	$ 2,090	$ 4,971	$ 9,175
Interest expense	(57)	(356)	(73)	(1,075)	(1,431)	(1,435)	(1,490)
Interest income	31	0	44	16	17	557	1,600
Common stock warrants - financing costs amortization	(21)	0	(51)	0
Total	(47)	(356)	(80)	(1,059)	(1,414)	(878)	110
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expenses	210	252	620	1,061	1,465	1,132	2,190
Selling, General, and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expenses	$ 825	$ 984	$ 2,270	$ (196)	$ 625	$ 3,839	$ 6,985

Income Taxes - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Income Taxes [Line Items]
Income tax operating loss carryforwards	$ 228,500
Income tax operating loss carryforwards not expired	131,300
Income tax operating loss carryforwards, expire between 2032 and 2037	41,900
Liability for uncertain tax positions	$ 0
Earliest Tax Year [Member] \| R&D Credit Carryovers [Member]
Income Taxes [Line Items]
Tax credit carryovers expiration year	2028
Latest Tax Year [Member] \| R&D Credit Carryovers [Member]
Income Taxes [Line Items]
Tax credit carryovers expiration year	2041
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Income tax operating loss carryforwards	$ 55,200
State and Local Jurisdiction [Member] \| R&D Credit Carryovers [Member]
Income Taxes [Line Items]
Tax credit carryovers	$ 1,100
State and Local Jurisdiction [Member] \| Earliest Tax Year [Member]
Income Taxes [Line Items]
Income tax operating loss carryforwards, expiration year	2027
State and Local Jurisdiction [Member] \| Latest Tax Year [Member]
Income Taxes [Line Items]
Income tax operating loss carryforwards, expiration year	2041
Federal [Member]
Income Taxes [Line Items]
Income tax operating loss carryforwards	$ 173,300
Federal [Member] \| R&D Credit Carryovers [Member]
Income Taxes [Line Items]
Tax credit carryovers	$ 2,300
Federal [Member] \| Earliest Tax Year [Member]
Income Taxes [Line Items]
Income tax operating loss carryforwards, expiration year	2032
Federal [Member] \| Latest Tax Year [Member]
Income Taxes [Line Items]
Income tax operating loss carryforwards, expiration year	2037

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue	$ 42	$ 7,762	$ 115	$ 24,044	$ 25,987	$ 23,851	$ 7,296
Costs of goods sold	0	8,281	0	26,553	28,557	35,127	9,280
Gross profit	42	(519)	115	(2,509)	(2,570)	(11,276)	(1,984)
Operating expenses:
Research and development	3,016	2,579	9,207	8,473	11,335	11,082	12,213
Selling, general, and administrative	3,229	3,859	9,965	11,640	15,382	20,537	24,138
Management fees					45	252	1,338
Restructuring costs					0	685	0
Total operating expenses	6,245	6,438	19,172	20,113	26,762	32,556	37,689
Loss from operations	(6,203)	(6,957)	(19,057)	(22,622)	(29,332)	(43,832)
Gain upon extinguishment of Payroll Protection Program Loan	0	0	0	1,528	1,528	0	(39,673)
Interest, net	(47)	(356)	(80)	(1,059)	(1,414)	(878)	110
Non-operating income (expenses)	300	6	5,083	11	19	(126)	(49)
Loss before income taxes	(5,950)	(7,307)	(14,054)	(22,142)	(29,199)	(44,836)	(39,612)
Income taxes	0	0	0	0	0	0	0
Net loss	$ (5,950)	$ (7,307)	$ (14,054)	$ (22,142)	$ (29,199)	$ (44,836)	$ (39,612)
Earnings Per Share, Basic	$ (0.13)	$ (0.2)	$ (0.31)	$ (0.6)	$ (0.78)	$ (1.32)	$ (1.21)
Earnings Per Share, Diluted	$ (0.13)	$ (0.2)	$ (0.31)	$ (0.6)	$ (0.78)	$ (1.32)	$ (1.21)
Weighted Average Number of Shares Outstanding, Basic	46,784,445	37,279,703	45,173,455	37,205,655	37,475,763	33,882,406	32,805,684
Weighted Average Number of Shares Outstanding, Diluted	46,784,445	37,279,703	45,173,455	37,205,655	37,475,763	33,882,406	32,805,684
Anti-dilutive stock options, restricted stock units, performance stock units, and common stock warrants	15,997,260	5,966,488	15,997,260	5,966,488	6,001,405	5,522,418	5,606,552

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

Text Block [Abstract]

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk

3. FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE AND CONCENTRATIONS OF CREDIT RISK

Financial Instruments Measured at Fair Value and Financial Statement Presentation

Financial instruments including cash and cash equivalents, restricted cash, accounts payable, and all other current liabilities have carrying values that approximate fair value. The Company measures common stock warrants on a quarterly basis. The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as of the measurement date as follows:

Level 1: Fair values are based on unadjusted quoted prices in active trading markets for identical assets and liabilities.

Level 2: Fair values are based on observable quoted prices other than those in Level 1, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.

Level 3: Fair values are based on at least one significant unobservable input for the asset or liability.

Fair Value Measurements and Financial Statement Presentation

The fair values of the Company’s financial instruments measured at fair value and their respective levels in the fair value hierarchy as of September 30, 2022, were as follows:


	September 30, 2022								September 30, 2022
	Fair Values of Assets								Fair Values of Liabilities
In Thousands	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Other items reported at fair value:
Common stock warrants	$	—	$	—	$	—	$	—	$	—	$	—	$	402	$	402

Total	$	—	$	—	$	—	$	—	$	—	$	—	$	402	$	402

The Company estimates the fair value of each Common Warrant as of the date of issuance and at the end of every fiscal period using a Black-Scholes option pricing model, which requires it to make predictive assumptions regarding future stock price volatility and dividend yield. The Company estimates the risk-free interest rate based on the United States Treasury zero-coupon yield curve for the remaining life of the Common Warrant. The Company estimates its future stock price volatility using its historical volatility over the remaining life of the Common Warrant. The Company does not pay dividends and does not expect to pay dividends in the foreseeable future.

The estimated fair values of the Common Warrants, and the assumptions used for the Black-Scholes option pricing model were as follows:


	As of September 30, 2022

Estimated fair value of Common Warrants	$	0.05
Assumptions:
Risk-free interest rate		4.1	%
Expected volatility		85.0	%
Expected term to liquidation (in years)		4.9

As of September 30, 2022, the Company had no other financial instruments measured at fair value.

The non-current portion of the Company’s financing lease obligations are also considered a financial instrument, which the Company measures at fair value for disclosure purposes. It is a Level 2 liability and as of December 31, 2021, it had a fair value of

$14.5

million. There is no non-current portion of the financing lease obligation at September 30, 2022.

Foreign Exchange Risk

Concentrations of Credit Risk

The Company invests its cash, cash equivalents, and restricted cash in highly liquid securities and investment funds. The Company diversifies the risk associated with investing in securities by allocating its investments to a diverse portfolio of short-dated, high investment-grade securities, which it classifies as short-term investments that are recorded at fair value in its consolidated financial statements. The Company maintains the credit risk in this portfolio in accordance with its internal policies and if necessary, makes changes to investments to minimize credit risk. The Company has not experienced any counterparty credit losses. As of September 30, 2022, the Company did not hold any short-term investments.

3. FINANCIAL INSTRUMENTS AND FAIR VALUE

Financial Instruments Measured at Fair Value and Financial Statement Presentation

Financial instruments including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and all other current liabilities have carrying values that approximate fair value. The Company measures short-term investments and commodity derivative contracts at fair value on a recurring basis. The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as of the measurement date as follows:

Level 1: Fair values are based on unadjusted quoted prices in active trading markets for identical assets and liabilities.

Level 3: Fair values are based on at least one significant unobservable input for the asset or liability.

Fair Value Measurements and Financial Statement Presentation

As of December 31, 2021, the Company had no financial instruments measured at fair value. The fair values of the Company’s financial instruments measured at fair value and their respective levels in the fair value hierarchy as of December 31, 2020, were as follows:


	December 31, 2020								December 31, 2020
	Fair Values of Assets								Fair Values of Liabilities
In Thousands	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Other items reported at fair value:
Short-term investments	$	11,698	$	—	$	—	$	11,698	$	—	$	—	$	—	$	—
Commodity derivative contracts		467		—		—		467		—		—		—		—

Total	$	12,165	$	—	$	—	$	12,165	$	—	$	—	$	—	$	—

The non-current portion of the Company’s financing lease obligations

are also considered a financial instrument, which it measures at fair value for disclosure purposes on a

non-recurring

basis. It is a Level 2 liability and had a fair value of $14.5 million as of December 31, 2021, and a fair value of $15.2 million as of December 31, 2020.

As of December 31, 2021, the Company held no short-term investments. All of the Company’s short-term investments as of December 31, 2020, were in corporate debt securities.

Commodity Price Risk

Under the Company’s former go-to-market strategy for its soybean

product line, it entered into hedging contracts to convert fixed price grain inventories and fixed price grain production agreements to floating prices, consistent with how the grain was sold. These hedging contracts allowed the counterparty to fix their sales prices at various times as defined in the contract. As a result of the continued wind-down of the soybean product line, the Company held no commodity derivative contracts as of December 31, 2021. As of December 31, 2020, the Company held commodity contracts with a notional amount of $12.8 million. The Company had no unrealized losses as of December 31, 2021, and $2.0 million of unrealized losses as of December 31, 2020.

Basis of Presentation & Summary of Significant Accounting Policies (Policies)

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

Accounting Policies [Abstract]

Use of Estimates

Basis of Presentation and Use of Estimates

The Company has prepared its Consolidated Financial Statements according to accounting principles generally accepted in the United States and has included the accounts of Calyxt and its subsidiary.

Cash, Cash Equivalents, and Restricted Cash

Cash, Cash Equivalents, Restricted Cash, and Investments

available-for-sale

Accounts Receivable

evaluation of specific accounts and will provide an allowance for credit losses when collection becomes doubtful. The Company performs credit evaluations of its customers’ financial condition on an

as-needed

basis. Payment is generally due fifteen or thirty days from the invoice date depending upon the product, and accounts pa

st 30

days are individually analyzed for collectability. When all collection efforts have been exhausted, the account is written off.

Inventory

The Company evaluates inventory balances for obsolescence or estimated net realizable value on a regular basis based on the age of the inventory and its sales forecasts. At each

period-end,

Prior to the commercialization of its high oleic soybean products, the Company expensed all grain costs as R&D.

Warrants

Forward Purchase Contracts

Under the Company’s former

go-to-market

Land, Buildings, and Equipment


Buildings and improvements		10- 20 years
Leasehold improvements		Shorter of lease term or 15 years
Office furniture and equipment		7 years
Assets under capital lease		4 - 20 years
Computer equipment and software		3- 5 years
Vehicles		3- 6 years

Revenue Recognition

The Company generally does not incur costs to obtain new contracts.

Performance Obligations

The following is a description of the principal goods and services from which the Company generates revenue:

Product Sales

Technology Licensing

The Company recognizes revenue from license agreements, which may consist of nonrefundable

up-front

payments, milestone payments, annual licensing fee payments, royalty payments, and payments for services.

Nonrefundable

up-front

Product Development Agreements

The Company recognizes revenue from product development agreements, which may consist of nonrefundable

up-front

payments, milestone payments, annual payments, and payments for services.

Nonrefundable

up-front

Agreements for the performance of research and development services and cost reimbursements are recognized as revenue over time based on work performed.

Collaborative Arrangements

in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. The Company had no such arrangements as of December 31, 2021.

Advertising Costs

The Company expenses advertising costs as incurred.

Research and Development (R&D)

Research and Development Expenses

The Company recognizes R&D expenses as incurred. These expenses consist of direct costs for R&D and

R&D-related

allocations of overhead costs such as facilities and information technology costs. Costs incurred in connection wit

h customer-fun

Patents

in-license,

and defend patents are recorded as SG&A expenses in the statements of operations.

Stock Based Compensation

Stock-Based Compensation

year-to-year

because of changes in those factors and because a new comparable company may become publicly traded.

Income Taxes

Current income taxes are recorded based on statutory obligations for the current operating period for the jurisdictions in which the Company has operations.

Foreign Currency Transactions

Transactions in foreign currencies are translated at the exchange rates effective on the transaction dates. Assets and liabilities denominated in foreign currencies are translated at the

period-end

exchange rate. Foreign currency gains and losses are recognized in

non-operating

expenses in the consolidated statements of operations.

Net Loss Per Share

Impairment of Long-Lived Assets

Impairment of Long-Lived Ass

ets

Impairment of Long-Lived Assets

Recently Issued Accounting Pronouncements

corresponding recognition of allowance for losses on trade and

other receivables

Recently Issued Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU)

No. 2016-02,

“Leases (Topic 842)” (ASU

2016-02).

Under ASU

2016-02,

In June 2016, the FASB issued ASU

No. 2016-13,

“Financial Instruments – Credit Losses (Topic 326)” (ASU

2016-13).

ASU

2016-13

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Performance Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 1,035	$ 1,236	$ 2,890	$ 865	$ 2,090	$ 4,971	$ 9,175
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 171	$ 122	$ 478	$ (133)	$ 16	$ 445	$ 225

Supplemental Information - Summary of Certain Balance Sheet Amounts (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts Receivable:
Accounts receivable			$ 0	$ 4,317
Allowance for doubtful accounts			0	0
Total			0	4,887
Inventory:
Raw materials			0	1,383
Total			0	1,383
Total land, buildings, and equipment			29,459	28,406
Less accumulated depreciation and amortization			(7,728)	(5,546)
Total		$ 4,859	21,731	22,860
Cash and cash equivalents		7,031	13,823	17,299	$ 58,610
Restricted cash	$ 100	174	499	393
Non-current restricted cash		0	99	597	1,040
Total		$ 7,205	14,421	29,987	$ 60,038
Land Under Capital Lease [Member]
Inventory:
Total land, buildings, and equipment			5,690	5,690
Buildings [Member]
Inventory:
Total land, buildings, and equipment			804	650
Buildings Under Capital Lease [Member]
Inventory:
Total land, buildings, and equipment			3,812	3,812
Leasehold Improvements [Member]
Inventory:
Total land, buildings, and equipment			215	160
Leasehold Improvements Under Capital Lease [Member]
Inventory:
Total land, buildings, and equipment			10,023	10,023
Office Furniture and Equipment [Member]
Inventory:
Total land, buildings, and equipment			5,409	4,813
Office Furniture and Equipment Under Capital Lease [Member]
Inventory:
Total land, buildings, and equipment			1,788	1,788
Computer Equipment and Software [Member]
Inventory:
Total land, buildings, and equipment			831	83
Construction in Progress [Member]
Inventory:
Total land, buildings, and equipment			849	1,329
Vehicles [Member]
Inventory:
Total land, buildings, and equipment			38	58
Growers [Member]
Accounts Receivable:
Accounts receivable			$ 0	$ 570

Long-Term Debt - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Apr. 19, 2020
Debt Instrument [Line Items]
Gain on extinguishment of loan	$ 0	$ 0		$ 0	$ 1,528	$ 1,528	$ 0	$ (39,673)
Paycheck Protection Program Loan CARES Act [Member]
Debt Instrument [Line Items]
Loan, face amount									$ 1,500
Forgiveness eligibility description						In order to be eligible for forgiveness, the proceeds of the PPP loan were required to be applied to certain eligible expenses, including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, with not more than 40 percent of the amount applied to non-payroll costs.
Description of loan forgiveness status						The Company applied the proceeds from the PPP loan toward qualifying expenses. On October 21, 2020, as modified December 29, 2020, the Company applied for forgiveness of the full principal amount and all accrued interest. On April 8, 2021, the Company was notified by the SBA that the full principal amount and all accrued interest of the PPP loan had been forgiven. Accordingly, the Company recognized a gain upon the extinguishment of the PPP loan for $1.5 million during the second quarter of 2021.
Gain on extinguishment of loan			$ 1,500

Cover Page	9 Months Ended
Cover Page	Sep. 30, 2022
Document Information [Line Items]
Document Type	S-4
Amendment Flag	false
Entity Registrant Name	Calyxt, Inc.
Entity Central Index Key	0001705843
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false

Employee Benefit Plan

12 Months Ended

Dec. 31, 2021

Postemployment Benefits [Abstract]

Employee Benefit Plan

9. EMPLOYEE BENEFIT PLAN

The Company provides a 401(k) defined contribution plan for all regular full-time employees who have completed two months of service. The Company matches employee contributions up to certain amounts and those matching contributions

est immediately.


	Year ended December 31,
In Thousands	2021		2020		2019
Employee benefit plan expenses	$	274	$	309	$	228

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2022

Text Block [Abstract]

Disclosure of Warrants Transactions

Warrant transactions for the nine months ended September 30, 2022, are as follows:


	Number of Pre- Funded Warrants		Weighted Average Exercise Price		Number of Common Warrants		Weighted Average Exercise Price
Outstanding as of December 31, 2021:

Issued		3,880,000	$	0.0001		7,760,000	$	1.41
Forfeited/canceled		—		—		—		—
Exercised		3,880,000	$	0.0001		—

Outstanding as of September 30, 2022:		—		—		7,760,000	$	1.41

Exercisable as of September 30, 2022:		—		—		7,760,000	$	1.41

Income Taxes - Schedule of Deferred Tax Assets And Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Components of Deferred Tax Assets and Liabilities [Abstract]
Net operating losses	$ 38,671	$ 33,392	$ 24,852
Stock-based compensation	2,724	2,531	3,637
Financing lease obligations	3,820	4,574	4,640
Tax credit carry forwards	3,210	2,577	2,106
Compensation	514	339	97
Derivative liability	0	703	0
Other	143	391	307
Gross deferred tax assets	49,082	44,507	35,639
Less valuation allowance	(45,369)	(39,898)	(30,888)
Net deferred tax assets	3,713	4,609	4,751
Fixed assets	(3,667)	(4,609)	(4,746)
Other	(46)	0	(5)
Gross deferred tax liabilities	(3,713)	(4,609)	(4,751)
Net deferred tax asset or liability	$ 0

Basis of Presentation & Summary of Significant Accounting Policies - Schedule of Estimated Useful Life of Assets Used to Compute Depreciation Using the Straight-Line Method (Detail)	12 Months Ended
	Dec. 31, 2021
Buildings and Other Improvements [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of assets	10 years
Buildings and Other Improvements [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of assets	20 years
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of assets	15 years
Office Furniture and Equipment [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of assets	7 years
Assets under Capital Lease [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of assets	4 years
Assets under Capital Lease [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of assets	20 years
Computer Equipment and Software [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of assets	3 years
Computer Equipment and Software [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of assets	5 years
Vehicles [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of assets	3 years
Vehicles [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of assets	6 years

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating activities
Net loss	$ (14,054)	$ (22,142)	$ (29,199)	$ (44,836)	$ (39,612)
Adjustments to reconcile net loss to net cash used by operating activities:
Gain upon extinguishment of Payroll Protection Program Loan	0	(1,528)	(1,528)	0	39,673
Depreciation and amortization	1,158	1,776	2,338	1,869	1,607
Stock-based compensation	2,890	865	2,090	4,971	9,175
Unrealized (gain) loss on mark-to-market of common stock warrants	(5,009)
Changes in operating assets and liabilities:
Accounts receivable		4,681	4,887	(3,765)	(1,122)
Due to/from related parties	(34)	(617)	(594)	(211)	(882)
Inventory		(291)	1,383	1,211	(2,594)
Prepaid expenses and other current assets	297	2,873	3,331	(3,122)	493
Accounts payable	(188)	108	(360)	(148)	259
Accrued expenses	41	(1,742)	(2,542)	347	537
Accrued compensation	(166)	334	572	(231)	876
Other	(536)	1,029	811	243	(688)
Net cash used by operating activities	(15,601)	(14,654)	(18,811)	(43,672)	(31,951)
Investing activities
Sales and (purchases) of short-term investments, net			11,698	(11,698)	0
Proceeds from sales of short-term investments		11,698
Purchases of land, buildings, and equipment	(1,509)	(376)	(497)	(1,786)	(2,969)
Net cash (used by) provided by investing activities	(1,509)	11,322	11,201	(13,484)	(2,969)
Financing activities
Proceeds from the issuance of common stock and pre-funded warrants	11,209
Costs incurred related to the issuance of common stock, pre-funded warrants, and common warrants	(962)
Proceeds from common stock issuance			4,380	15,000	0
Costs incurred related to the issuance of stock			(501)	(963)	0
Proceeds from Payroll Protection Program loan			0	1,518	0
Repayments of financing lease obligations	(353)	(271)	(364)	(360)	(275)
Proceeds from the exercise of stock options	0	227	227	212	344
Costs incurred related to shares withheld for net settlement			0	0	(813)
Proceeds from sale and leaseback of land, buildings, and equipment			0	0	414
Net cash provided by (used by) financing activities	9,894	(44)	3,742	15,407	(330)
Net decrease in cash, cash equivalents, and restricted cash	(7,216)	(3,376)	(3,868)	(41,749)	(35,250)
Cash, cash equivalents, and restricted cash – beginning of period	14,421	18,289	18,289	60,038	95,288
Cash, cash equivalents, and restricted cash – end of period	$ 7,205	$ 14,913	$ 14,421	$ 18,289	$ 60,038

Long-Term Debt	12 Months Ended
Long-Term Debt	Dec. 31, 2021
Debt Disclosure [Abstract]
Long-Term Debt	12. LONG-TERM DEBT The Company’s long-term debt was comprised of a $1.5 million promissory note pursuant to the Paycheck Protection Program (the PPP loan) established by the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) implemented by the U.S. Small Business Administration (SBA). The Company received the funds under the PPP loan on April 19, 2020. Subject to certain conditions, the PPP loan and accrued interest were eligible to be forgiven in whole or in part by applying for forgiveness pursuant to the CARES Act and the Paycheck Protection Program. In order to be eligible for forgiveness, the proceeds of the PPP loan were required to be applied to certain eligible expenses, including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, with not more than 40 percent of the amount applied to non-payroll costs. The Company applied the proceeds from the PPP loan toward qualifying expenses. On October 21, 2020, as modified December 29, 2020, the Company applied for forgiveness of the full principal amount and all accrued interest. On April 8, 2021, the Company was notified by the SBA that the full principal amount and all accrued interest of the PPP loan had been forgiven. Accordingly, the Company recognized a gain upon the extinguishment of the PPP loan for $1.5 million during the second quarter of 2021.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Options Exercisable, Beginning Balance	2,789,110	2,347,665
Options Exercisable, Ending Balance	3,314,828	2,789,110
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 10.23	$ 10.15
Weighted-Average Exercise Price Per Share, Ending Balance	$ 9.88	$ 10.23
Options Outstanding, Beginning Balance	4,658,425	4,621,173
Options Outstanding, Granted	1,609,000	774,959
Options Outstanding, Exercised		(61,372)
Options Outstanding, Forfeited or expired	(420,606)	(676,335)
Options Outstanding, Ending Balance	5,846,799	4,658,425
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 9.47	$ 10.3
Weighted-Average Exercise Price Per Share, Granted	1.12	5.2
Weighted-Average Exercise Price Per Share, Exercised		3.7
Weighted-Average Exercise Price Per Share, Forfeited or expired	7.05	10.75
Weighted-Average Exercise Price Per Share, Ending Balance	$ 7.35	$ 9.47
Previously Reported [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Options Exercisable, Beginning Balance	2,789,110
Options Exercisable, Ending Balance		2,789,110
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 10.23
Weighted-Average Exercise Price Per Share, Ending Balance		$ 10.23
Options Outstanding, Beginning Balance	4,658,405
Options Outstanding, Ending Balance		4,658,405
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 9.47
Weighted-Average Exercise Price Per Share, Ending Balance		$ 9.47

Supplemental Information

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Supplemental Information

9. SUPPLEMENTAL INFORMATION

Certain statement of operations amounts are as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,
In Thousands	2022			2021			2022			2021
Stock-based compensation expense:
Research and development	$	210		$	252		$	620		$	1,061
Selling, general, and administrative		825			984			2,270			(196	)

Total	$	1,035		$	1,236		$	2,890		$	865


	Three Months Ended September 30,						Nine Months Ended September 30,
In Thousands	2022			2021			2022			2021
Interest, net:
Interest expense	$	(57	)	$	(356	)	$	(73	)	$	(1,075	)
Interest income		31			—			44			16
Common stock warrants - financing costs amortization		(21	)		—			(51	)		—

Total	$	(47	)	$	(356	)	$	(80	)	$	(1,059	)

Certain balance sheet amounts are as follows:


In Thousands	As of September 30, 2022		As of December 31, 2021
Cash, cash equivalents, and restricted cash:
Cash and cash equivalents	$	7,031	$	13,823
Restricted cash		174		499
Non-current restricted cash		—		99

Total	$	7,205	$	14,421

Supplemental statement of cash flows information is as follows:


	As of September 30,
In Thousands	2022		2021
Interest paid	$	67		1,072

Non-cash transactions not reported in the consolidated statement of cash flows is as follows:


	As of September 30,
In Thousands	2022			2021
Receivable from Jefferies for shares issued under ATM Facility	$	(260	)	$	—
Non-cash additions to land, buildings, and equipment	$	(687	)	$	—
Cumulative effect of adoption of lease accounting standard on stockholders’ equity	$	832		$	—
Establishment of operating lease right-of-use assets and associated operating lease liabilities	$	14,090		$	—

10. SUPPLEMENTAL INFORMATION

Certain balance sheet amounts are as follows:


	December 31,
In Thousands	2021		2020
Accounts Receivable:
Accounts receivable	$	—	$	4,317
Receivables from growers		—		570
Allowance for doubtful accounts		—		—

Total	$	—	$	4,887


	December 31,
In Thousands	2021		2020
Inventory:
Raw materials	$	—	$	1,383

Total	$	—	$	1,383


	December 31,
In Thousands	2021			2020
Land, buildings, and equipment:
Land under capital lease	$	5,690		$	5,690
Buildings		804			650
Buildings under capital lease		3,812			3,812
Leasehold improvements		215			160
Leasehold improvements under capital lease		10,023			10,023
Office furniture and equipment		5,409			4,813
Office furniture and equipment under capital lease		1,788			1,788
Computer equipment and software		831			83
Construction in progress		849			1,329
Vehicles		38			58

Total land, buildings, and equipment		29,459			28,406
Less accumulated depreciation and amortization		(7,728	)		(5,546	)

Total	$	21,731		$	22,860

Certain statements of operations amounts are as follows:


	Year Ended December 31,
In Thousands	2021		2020		2019
Revenue:
Soybean grain	$	25,930	$	12,976	$	—
Soybean meal		—		8,628		5,604
Soybean oil		—		2,220		1,685
Other		57		27		7

Total	$	25,987	$	23,851	$	7,296


	Year Ended December 31,
In Thousands	2021		2020		2019
Stock-based compensation expense:
Research and development	$	1,465	$	1,132	$	2,190
Selling, general, and administrative		625		3,839		6,985

Total	$	2,090	$	4,971	$	9,175


	Year Ended December 31,
In Thousands	2021			2020			2019
Interest, net:
Interest expense	$	(1,431	)	$	(1,435	)	$	(1,490	)
Interest income		17			557			1,600

Total	$	(1,414	)	$	(878	)	$	110

Certain statements of cash flows amounts are as follows:


	Year Ended December 31,
In Thousands	2021		2020		2019
Cash, cash equivalents, restricted cash, and short-term investments:
Cash and cash equivalents	$	13,823	$	17,299	$	58,610
Restricted cash		499		393		388
Non-current restricted cash		99		597		1,040

Cash, cash equivalents, and restricted cash		14,421		18,289		60,038
Short-term investments		—		11,698		—

Total	$	14,421	$	29,987	$	60,038


	Year Ended December 31,
In Thousands	2021		2020		2019
Supplemental investing and financing transactions:
Receivable from Jefferies for shares issued under ATM Facility	$	260	$	—	$	—

Interest paid	$	1,425	$	1,455	$	1,472

Non-cash additions to land, buildings, and equipment	$	691	$	—	$	414

Stock-Based Compensation - Stock Options - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options priced at fair market value, Percent	100.00%	100.00%
Stock option expiration period	10 years	10 years
2017 Omnibus Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	3 years
2017 Omnibus Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	6 years
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual term	5 years 3 months 18 days	5 years 7 months 6 days
Aggregate intrinsic value of options outstanding and exercisable	$ 0
Unrecognized stock-based compensation expense related to non-vested stock options	$ 3,700	$ 5,200
Unrecognized stock-based compensation expense, expected recognition weighted-average period	23 months	24 months

Supplemental Information (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Certain Statements of Operations Amounts

Certain statement of operations amounts are as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,
In Thousands	2022			2021			2022			2021
Stock-based compensation expense:
Research and development	$	210		$	252		$	620		$	1,061
Selling, general, and administrative		825			984			2,270			(196	)

Total	$	1,035		$	1,236		$	2,890		$	865


	Three Months Ended September 30,						Nine Months Ended September 30,
In Thousands	2022			2021			2022			2021
Interest, net:
Interest expense	$	(57	)	$	(356	)	$	(73	)	$	(1,075	)
Interest income		31			—			44			16
Common stock warrants - financing costs amortization		(21	)		—			(51	)		—

Total	$	(47	)	$	(356	)	$	(80	)	$	(1,059	)

Certain statements of operations amounts are as follows:


	Year Ended December 31,
In Thousands	2021		2020		2019
Revenue:
Soybean grain	$	25,930	$	12,976	$	—
Soybean meal		—		8,628		5,604
Soybean oil		—		2,220		1,685
Other		57		27		7

Total	$	25,987	$	23,851	$	7,296


	Year Ended December 31,
In Thousands	2021		2020		2019
Stock-based compensation expense:
Research and development	$	1,465	$	1,132	$	2,190
Selling, general, and administrative		625		3,839		6,985

Total	$	2,090	$	4,971	$	9,175


	Year Ended December 31,
In Thousands	2021			2020			2019
Interest, net:
Interest expense	$	(1,431	)	$	(1,435	)	$	(1,490	)
Interest income		17			557			1,600

Total	$	(1,414	)	$	(878	)	$	110

Schedule of Certain Balance Sheet Amounts

Certain balance sheet amounts are as follows:


In Thousands	As of September 30, 2022		As of December 31, 2021
Cash, cash equivalents, and restricted cash:
Cash and cash equivalents	$	7,031	$	13,823
Restricted cash		174		499
Non-current restricted cash		—		99

Total	$	7,205	$	14,421

Certain balance sheet amounts are as follows:


	December 31,
In Thousands	2021		2020
Accounts Receivable:
Accounts receivable	$	—	$	4,317
Receivables from growers		—		570
Allowance for doubtful accounts		—		—

Total	$	—	$	4,887


	December 31,
In Thousands	2021		2020
Inventory:
Raw materials	$	—	$	1,383

Total	$	—	$	1,383


	December 31,
In Thousands	2021			2020
Land, buildings, and equipment:
Land under capital lease	$	5,690		$	5,690
Buildings		804			650
Buildings under capital lease		3,812			3,812
Leasehold improvements		215			160
Leasehold improvements under capital lease		10,023			10,023
Office furniture and equipment		5,409			4,813
Office furniture and equipment under capital lease		1,788			1,788
Computer equipment and software		831			83
Construction in progress		849			1,329
Vehicles		38			58

Total land, buildings, and equipment		29,459			28,406
Less accumulated depreciation and amortization		(7,728	)		(5,546	)

Total	$	21,731		$	22,860

Schedule of Statements of Certain Statements of Cash Flows Amounts

Supplemental statement of cash flows information is as follows:


	As of September 30,
In Thousands	2022		2021
Interest paid	$	67		1,072

Non-cash transactions not reported in the consolidated statement of cash flows is as follows:


	As of September 30,
In Thousands	2022			2021
Receivable from Jefferies for shares issued under ATM Facility	$	(260	)	$	—
Non-cash additions to land, buildings, and equipment	$	(687	)	$	—
Cumulative effect of adoption of lease accounting standard on stockholders’ equity	$	832		$	—
Establishment of operating lease right-of-use assets and associated operating lease liabilities	$	14,090		$	—

Certain statements of cash flows amounts are as follows:


	Year Ended December 31,
In Thousands	2021		2020		2019
Cash, cash equivalents, restricted cash, and short-term investments:
Cash and cash equivalents	$	13,823	$	17,299	$	58,610
Restricted cash		499		393		388
Non-current restricted cash		99		597		1,040

Cash, cash equivalents, and restricted cash		14,421		18,289		60,038
Short-term investments		—		11,698		—

Total	$	14,421	$	29,987	$	60,038


	Year Ended December 31,
In Thousands	2021		2020		2019
Supplemental investing and financing transactions:
Receivable from Jefferies for shares issued under ATM Facility	$	260	$	—	$	—

Interest paid	$	1,425	$	1,455	$	1,472

Non-cash additions to land, buildings, and equipment	$	691	$	—	$	414

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
ATM Facility Member
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs		$ 0.5
Follow-on Public Offering [Member]
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 0.5		$ 1.0

Leases, Commitments, and Contingencies - Additional Information (Detail) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($) ft²	Dec. 31, 2021 USD ($) ft²	Dec. 31, 2017 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Other Commitments [Line Items]
Lease term		20 years
Number of lease extension options		4
Extension term of lease agreement		5 years
Proceeds from sale of land and uncompleted facility			$ 7,000
Percentage of annual base rent		8.00%
Increase in percentage of annual base rent on the sixth, eleventh and sixteenth anniversaries		7.50%
Annual base rent		$ 1,400
Restricted cash		499		$ 393	$ 388
Roseville, MN Lease [Member]
Other Commitments [Line Items]
Lessee, Operating Lease, Remaining Lease Term	15 years 7 months 6 days
Maximum [Member] \| Roseville, MN Lease [Member]
Other Commitments [Line Items]
Lessee, Operating Lease, Remaining Lease Term	5 years
Cellectis [Member]
Other Commitments [Line Items]
Minimum net worth required	$ 300,000	$ 300,000
Cellectis [Member] \| Maximum [Member]
Other Commitments [Line Items]
Threshold percentage of ownership in outstanding common stock to enact indemnification agreement	50.00%	50.00%
Corporate Headquarters [Member]
Other Commitments [Line Items]
Office and lab building area \| ft²	38,000	44,000
Option to extend		true
Option to extend, description		The lease has a term of twenty years with four options to extend its term for five years each subject to there being no default under the lease terms beyond any cure period and the Company occupying the property at the time of extension.
Equipment [Member]
Other Commitments [Line Items]
Option to extend		true
Restricted cash	$ 200	$ 600
Aggregate payments for equipment financing		$ 600
Financing arrangement payment period		21 months

Stock-Based Compensation - Summary of Stock-Based Compensation Expense Related to Stock Option Awards (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 1,035	$ 1,236	$ 2,890	$ 865	$ 2,090	$ 4,971	$ 9,175
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 530	$ 698	$ 1,420	$ 1,103	$ 1,850	$ 3,371	$ 6,035

Employee Benefit Plan - Summary of Defined Contribution Plan (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Employee benefit plan expenses	$ 274	$ 309	$ 228